var title_f20_26_20896="Normal vision";
var content_f20_26_20896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal vision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The eye's optical system focuses light on to the retina primarily due to the shape of the cornea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20896=[""].join("\n");
var outline_f20_26_20896=null;
var title_f20_26_20897="Eruptive syringoma - neck";
var content_f20_26_20897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eruptive syringoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple flesh-colored and erythematous small papules are present on the neck and chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20897=[""].join("\n");
var outline_f20_26_20897=null;
var title_f20_26_20898="Patient information: Addisons disease (The Basics)";
var content_f20_26_20898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15599\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27424\">",
"         Endocrine glands",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/19/11570\">",
"         Patient information: Adrenal crisis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/61/6099\">",
"         Patient information: Cushing's syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/0/9220\">",
"         Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Addison&rsquo;s disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/addisons-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1752427451\">",
"      <span class=\"h1\">",
"       What is Addison&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Addison&rsquo;s disease is a condition that can cause people to lose weight, and feel tired and weak.",
"     </p>",
"     <p>",
"      Addison&rsquo;s disease occurs when the body&rsquo;s adrenal glands do not work normally. The adrenal glands are small organs that are located on top of each kidney (",
"      <a class=\"graphic graphic_figure graphicRef67279 \" href=\"UTD.htm?26/50/27424\">",
"       figure 1",
"      </a>",
"      ). Normally, the adrenal glands make substances called hormones. These hormones do many things in the body, such as help keep blood sugar levels and blood pressure normal. In people with Addison&rsquo;s disease, the adrenal glands do not work properly and do not make enough hormones. This causes symptoms.",
"     </p>",
"     <p>",
"      Some people have symptoms similar to those of Addison&rsquo;s disease, but their symptoms have a different cause. Normally, adrenal glands make hormones after they receive signals from the brain. Some people have problems in the brain that cause these signals to be abnormal. Then, the adrenal glands do not make enough hormones.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1752427458\">",
"      <span class=\"h1\">",
"       What are the symptoms of Addison&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with Addison&rsquo;s disease have the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling tired or weak",
"       </li>",
"       <li>",
"        Weight loss and loss of appetite",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other common symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Darkening of the skin, especially on the face, neck, and back of the hands",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Feeling light-headed or dizzy when standing or sitting up",
"       </li>",
"       <li>",
"        Muscle and joint pain",
"       </li>",
"       <li>",
"        Craving salty foods",
"       </li>",
"       <li>",
"        Losing hair from the armpits and pubic area (in women)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, a person&rsquo;s symptoms can become severe and life-threatening. Doctors call this &ldquo;adrenal crisis.&rdquo; Symptoms of adrenal crisis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever and weakness",
"       </li>",
"       <li>",
"        Nausea, vomiting, and stomach pain",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Passing out, or going into shock",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Adrenal crisis usually occurs when a person&rsquo;s body is under stress, such as from an infection or injury.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1752427465\">",
"      <span class=\"h1\">",
"       Is there a test for Addison&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse might order different tests to check for Addison&rsquo;s disease. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood or saliva tests",
"       </li>",
"       <li>",
"        Hormone tests to see if the adrenal glands can work normally",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1752427472\">",
"      <span class=\"h1\">",
"       How is Addison&rsquo;s disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Addison&rsquo;s disease is treated with hormone medicines to replace the hormones that are missing in the body. People usually need to take these medicines every day for the rest of their life.",
"     </p>",
"     <p>",
"      It is important to let your doctor or nurse know if you have any side effects from the medicines or develop any new symptoms.",
"     </p>",
"     <p>",
"      Your doctor might also prescribe emergency medicine that you should keep with you at all times in case you have adrenal crisis. This medicine comes in the form of a shot. If you think you are having adrenal crisis, use the medicine and then",
"      <strong>",
"       call 9-1-1 for an ambulance",
"      </strong>",
"      . Your doctor might recommend that you also use this emergency medicine if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a major injury, for example if you break a bone or lose a lot of blood",
"       </li>",
"       <li>",
"        Pass out",
"       </li>",
"       <li>",
"        Vomit up your daily medicine",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1752427479\">",
"      <span class=\"h1\">",
"       What if I get sick or know that I am going to have surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you get sick or know that you are going to have surgery, talk with your doctor or nurse. For example, if you are vomiting and unable to keep your medicines down, let your doctor or nurse know. When people are sick or have surgery, their body might need more adrenal hormones than usual. Your doctor or nurse will tell you if you need to increase your medicines, and how and when to do it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1752427486\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. Most women with Addison&rsquo;s disease are able to get pregnant and have a baby. But your doctor will want to follow you closely. He or she might make changes in your medicine dose during the pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1752427493\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with Addison&rsquo;s disease lead an active and normal life. But to stay as healthy as possible, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Follow your doctor&rsquo;s instructions about treatment",
"       </li>",
"       <li>",
"        Carry an emergency medicine shot with you, especially if you travel to areas that are not near a hospital",
"       </li>",
"       <li>",
"        Learn about the symptoms of adrenal crisis so that you will know when to treat it or get help",
"       </li>",
"       <li>",
"        Wear a medical alert bracelet, and carry an emergency medical card",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1752427500\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"       Patient information: Cushing's syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/19/11570?source=see_link\">",
"       Patient information: Adrenal crisis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=see_link\">",
"       Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/26/20898?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15599 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20898=[""].join("\n");
var outline_f20_26_20898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427451\">",
"      What is Addison&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427458\">",
"      What are the symptoms of Addison&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427465\">",
"      Is there a test for Addison&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427472\">",
"      How is Addison&rsquo;s disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427479\">",
"      What if I get sick or know that I am going to have surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427486\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427493\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752427500\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27424\">",
"      Endocrine glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/19/11570?source=related_link\">",
"      Patient information: Adrenal crisis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/0/9220?source=related_link\">",
"      Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=related_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_26_20899="Suture placement Coopers ligmnt";
var content_f20_26_20899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Suture placement through Cooper's ligament for Burch procedure (retropubic colposuspension)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. Mann, WJ, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.714.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20899=[""].join("\n");
var outline_f20_26_20899=null;
var title_f20_26_20900="Cryoablation of lung tumors";
var content_f20_26_20900=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cryoablation of lung tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20900/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20900/contributors\">",
"     William Moore, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20900/contributors\">",
"     Thomas V Bilfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20900/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20900/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20900/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20900/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20900/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20900/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/26/20900/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoablation is a minimally invasive technique that has shown promise in patients with non-small cell lung cancer (NSCLC), as well as in those with a limited number of small pulmonary metastases. Cryoablation is limited to situations in which surgical resection is not an option due to advanced age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coexistent medical morbidities.",
"   </p>",
"   <p>",
"    Other treatment options in these settings include external beam radiation therapy (RT), stereotactic body radiotherapy, or radiofrequency ablation (RFA). These approaches may result in clinically useful symptom palliation and improvements in survival. However, not all patients have access to these treatments and many may not be candidates due to medical comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"     \"Radiofrequency ablation of lung tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms of cellular cytotoxicity, the techniques of cryoablation therapy, and the early results with this technique are reviewed here. The management of patients with early stage NSCLC and the role of surgery in patients with lung metastases are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link\">",
"     \"Management of stage I and stage II non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF CYTOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of cellular destruction caused by cryotherapy include direct effects on tumor cells and indirect effects on tumor vasculature, both of which can contribute to coagulative necrosis in a tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When tissue is cooled rapidly, water cannot move out of the cell and there is intracellular ice formation, leading to further intracellular cooling and disruption of enzyme and cell membrane functions. If the temperature is kept low for a period of time, additional crystallization results, further damaging the cell.",
"     </li>",
"     <li>",
"      When there is slower cooling of tissue, ice forms in the extracellular matrix, creating a relatively hypertonic environment. Water thus leaves the cell by osmosis, causing intracellular dehydration. During the thawing process the water returns to the cell rapidly, resulting in lysis.",
"     </li>",
"     <li>",
"      Indirect damage to the tumor can be due to damage to the tumor's vascular supply. Direct damage to the small vessel walls can occur by the same cellular mechanisms that damage tumor cells. In addition, the small vessels near the tumor can swell during the freezing process, resulting in stasis. Following thawing, reperfusion injury may occur. These indirect effects are only seen in small blood vessels (&lt;3 mm). Larger blood vessels are protected from injury by the effects of blood flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the standard treatment approach for patients with early stage NSCLC; surgery is also used in selected patients with a limited number of small metastases. Patients may not be candidates for surgery, based upon impaired pulmonary function, other comorbidity, or age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to use cryoablation or another nonsurgical modality should be determined by a multidisciplinary group or a tumor board that includes a thoracic surgeon, a radiologist, a pulmonologist, a medical oncologist, and a radiation oncologist.",
"   </p>",
"   <p>",
"    Every effort should be made to identify those patients who will tolerate pulmonary resection. Although the level of acceptable risk for postoperative complications is somewhat subjective, preoperative tests provide criteria for defining a patient's risk, and thus for selecting those who might benefit from an alternative approach. Preoperative pulmonary evaluation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best results with cryotherapy and other ablative procedures are achieved in patients with tumors &lt;3 cm in size, and without evidence of lymph node involvement or extrapulmonary metastases. This size criterion is based upon data indicating that the best outcomes for NSCLC are in small cancers. Furthermore, the kill zone with the largest of the available cryoprobes is limited to 3 cm. Although more than one probe can be used to ablate larger lesions, the success rate is lower. Cryoablation is therefore particularly suited for patients with stage I NSCLC and those with solitary metastases. As with radiofrequency ablation, cryoablation may be useful in patients with larger tumors, particularly for palliation of pain, dyspnea, or cough. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"     \"Radiofrequency ablation of lung tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumor location is important. Tumors located in the outer one-third of the lung are better suited for cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/2\">",
"     2",
"    </a>",
"    ]. Such lesions usually can be reached by a transthoracic approach and are less likely to be in close proximity to large vascular or bronchial structures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/3\">",
"     3",
"    </a>",
"    ]. Cryoablation is preferable over radiofrequency ablation for lesions close to large vascular structures.",
"   </p>",
"   <p>",
"    Cryoablation has certain characteristics that may make it preferable to other ablative techniques in some patients. Cryoablation tends to be less painful than radiofrequency ablation. Furthermore, cryotherapy does not interfere with electrophysiologic devices such as pacemakers and defibrillators, unlike radiofrequency ablation. Cryoablation can be repeated if tumor recurs or the initial ablation is incomplete, which is not feasible with radiation therapy techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of uncorrectable coagulopathy is an absolute contraindications to cryoablation. Another factor that may mitigate against the use of cryoablation is the inability to tolerate general anesthesia, although the procedure can be performed with moderate sedation and local anesthesia.",
"   </p>",
"   <p>",
"    Patients with severe emphysema or pulmonary fibrosis may show significant intraalveolar hemorrhage subsequent to the procedure and respiratory failure. The inability to safely access the tumor with the probes, which currently are straight without any ability to bend, is a concern. Serious complications, including death, can occur. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Results'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoablation should destroy a margin of normal tissue surrounding the tumor as well as the tumor itself. Thus, the number and type of probes used depend upon the size of the area to be ablated. For example, a 2 cm lung cancer would need a -40 C kill zone of at least 2.5 to 3.0 cm.",
"   </p>",
"   <p>",
"    Computerized tomography (CT) is used to guide placement of the cryotherapy probe and to document appropriate probe placement. With currently available systems, a staged freeze-thaw-freeze cycle is performed on all tumors. This includes a ten minute freeze, an eight minute thaw, and a second ten minute freeze. This will result in the maximal size of ablation.",
"   </p>",
"   <p>",
"    Although most tumors are destroyed at -20 C, there are tumor cell lines that are resistant to temperatures as low as -40 C. Increased cell death is proportional to the amount of time at which the low temperatures are maintained. We currently use the estimated -40 C isotherm for treatment planning to obtain maximal tumor destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients are evaluated with CT at one, three, six, nine and twelve months, and yearly thereafter. Positron emission tomography (PET) is performed at six month intervals for the first two years and yearly thereafter.",
"   </p>",
"   <p>",
"    Changes are apparent on CT at the end of the procedure. The original lesion is usually surrounded by a parenchymal hemorrhage, which tends to resolve by three months. Cavitation and shrinkage of the original lesion are apparent at six months. CT densitometry before and after contrast administration is used to evaluate for the presence of residual or recurrent tumor. A CT scan should show little or no contrast enhancement (&lt;15 Hounsfield units). If there is a greater degree of enhancement, recurrence should be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successfully treated tumors should not demonstrate uptake on PET after six months. Uptake at the outer rim of the tumor lesions is particularly suspicious for recurrence, as is uptake in the hilum or mediastinum. Mediastinal uptake may necessitate restaging of the mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is extensive experience with cryoablation for the treatment of tumors in other sites (eg, prostate, kidney, liver), there are only limited data to provide insight into long-term outcomes for patients with lung tumors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short-term outcomes were reported from a Chinese series of 187 patients treated for 234 lesions (84 percent primary lung tumors and 16 percent metastases) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/5\">",
"       5",
"      </a>",
"      ]. For lesions &le;4 cm, cryotherapy successfully froze 99 and 87 percent of peripheral and central lesions, respectively. One week after cryoablation, lesion enlargement was present in 91 percent of cases, but by six months approximately 90 percent of lesions were either unchanged or decreased in size. The most important complications attributed to the procedure included hemoptysis, pleural effusion, and pneumothorax (62, 14 and 12 percent, respectively).",
"     </li>",
"     <li>",
"      Somewhat longer follow-up was available from a Japanese series of 20 patients treated for 35 tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/6\">",
"       6",
"      </a>",
"      ], At a median follow-up of 28 months, seven lesions in seven patients had recurred locally (20 percent of the treated lesions).",
"     </li>",
"     <li>",
"      In a study of 103 patients with biopsy-proven stage I NSCLC who were unfit for medical resection, the three-year survival rates were similar with sublobar resection, radiofrequency ablation, or cryoablation (87, 88, and 77 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/7\">",
"       7",
"      </a>",
"      ]. Local recurrence was 11 percent in the 27 patients managed with cryotherapy in this study. Pneumothorax was the most common complication with 37 percent of patients requiring chest tube placement. The mean length of stay was two days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intraalveolar hemorrhage is seen in almost all patients and may be quite extensive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20900/abstract/8\">",
"     8",
"    </a>",
"    ]. In severely compromised patients, this can lead to respiratory insufficiency, a need for intubation, or death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoablation is a technique that involves placement of a cryoprobe into a lesion in the lung, with freezing used to cause focal tissue destruction. Although currently available probes are approved for use in other body locations, cryoablation remains experimental for lung lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical resection is the standard treatment for patients with stage I and II non-small cell lung cancer (NSCLC) if pulmonary function is adequate and medical comorbidity does not preclude surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link\">",
"       \"Management of stage I and stage II non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are surgical candidates and have a single or limited number of lung metastases and no uncontrolled systemic disease, surgical resection is the standard therapeutic approach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have either a small primary NSCLC or a single or limited number of pulmonary metastases and are not candidates for surgery based upon age, underlying lung disease, other medical comorbidities, or who refuse surgery, cryoablation, radiofrequency ablation, or radiation therapy techniques may be useful depending upon the local availability of adequate expertise. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Results'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of stage I and stage II non-small cell lung cancer\", section on 'Nonsurgical approaches'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link&amp;anchor=H5#H5\">",
"       \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Lung tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are not surgical candidates and either have small non-small cell lung cancers or limited number of small lung metastases, ablative techniques represent an important option. These techniques include cryoablation, radiofrequency ablation (RFA), external beam radiation therapy, and stereotactic body radiation therapy (SBRT). Further experience and longer follow-up with cryoablation is required to determine its role relative to other ablative techniques.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/1\">",
"      Hoffman, NE, Bischof, JC. The Cryobiology of cryosurgical injury. Urol 2002; 60(supple 2a):40-49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/2\">",
"      Cesaretti JA, Pennathur A, Rosenstein BS, et al. Stereotactic radiosurgery for thoracic malignancies. Ann Thorac Surg 2008; 85:S785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/3\">",
"      Yankelevitz DF, Vazquez M, Henschke CI. Special techniques in transthoracic needle biopsy of pulmonary nodules. Radiol Clin North Am 2000; 38:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/4\">",
"      Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000; 214:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/5\">",
"      Wang H, Littrup PJ, Duan Y, et al. Thoracic masses treated with percutaneous cryotherapy: initial experience with more than 200 procedures. Radiology 2005; 235:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/6\">",
"      Kawamura M, Izumi Y, Tsukada N, et al. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. J Thorac Cardiovasc Surg 2006; 131:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/7\">",
"      Zemlyak A, Moore WH, Bilfinger TV. Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. J Am Coll Surg 2010; 211:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20900/abstract/8\">",
"      Ahmed A, Littrup P. Percutaneous cryotherapy of the thorax: safety considerations for complex cases. AJR Am J Roentgenol 2006; 186:1703.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4616 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20900=[""].join("\n");
var outline_f20_26_20900=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF CYTOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=related_link\">",
"      Radiofrequency ablation of lung tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_26_20901="Almotriptan: Drug information";
var content_f20_26_20901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Almotriptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/4/22597?source=see_link\">",
"    see \"Almotriptan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32388?source=see_link\">",
"    see \"Almotriptan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Axert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Axert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       1B, 1D",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral: Initial: 6.25-12.5 mg in a single dose; if the headache returns, repeat the dose after 2 hours; no more than 2 doses (maximum daily dose: 25 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The safety of treating more than 4 migraines/month has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant use of an enzyme inhibitor:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients receiving a potent CYP3A4 inhibitor:",
"     </i>",
"     Initial: 6.25 mg in a single dose; maximum daily dose: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients with renal impairment and concomitant use of a potent CYP3A4 inhibitor:",
"     </i>",
"     Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients with hepatic impairment and concomitant use of a potent CYP3A4 inhibitor:",
"     </i>",
"     Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7827063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32388?source=see_link\">",
"      see \"Almotriptan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F131848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute): Initial: 6.25 mg in a single dose; maximum daily dose: 12.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F131849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: 6.25 mg in a single dose; maximum daily dose: 12.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Axert&reg;: 6.25 mg, 12.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9405718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute treatment of migraine with or without aura in adults (with a history of migraine) and adolescents (with a history of migraine lasting &ge;4 hours when left untreated)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Axert&reg; may be confused with Antivert&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (&le;5%), dizziness (&le;4%), headache (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1% to 3%), vomiting (&le;2%), xerostomia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic shock, angina, angioedema, breast pain, colitis, coronary artery vasospasm, hemiplegia, hypertension, myocardial ischemia, MI, neuropathy, rash, seizure, syncope, tachycardia, ventricular fibrillation, ventricular tachycardia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to almotriptan or any component of the formulation; hemiplegic or basilar migraine; known or suspected ischemic heart disease (eg, angina pectoris, MI, documented silent ischemia, coronary artery vasospasm, Prinzmetal's variant angina); cerebrovascular syndromes (eg, stroke, transient ischemic attacks); peripheral vascular disease (eg, ischemic bowel disease); uncontrolled hypertension; use within 24 hours of another 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist; use within 24 hours of ergotamine derivatives and/or ergotamine-containing medications (eg, dihydroergotamine, ergotamine)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions following 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration in patients with and without a history of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Transient and permanent blindness and partial vision loss have been reported (rare) with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Almotriptan contains a sulfonyl group which is structurally different from a sulfonamide.  Cross-reactivity in patients with sulfonamide allergy has not been evaluated; however, the manufacturer recommends that caution be exercised in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Almotriptan should not be given to patients with documented ischemic or vasospastic CAD. Patients with risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) should undergo adequate cardiac evaluation prior to administration; if the cardiac evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). All patients should undergo periodic evaluation of cardiovascular status during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Drug clearance may be reduced leading to increased plasma concentrations; dosage reduction is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal failure. Drug clearance may be reduced leading to increased plasma concentrations; dosage reduction is recommended for severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce almotriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended. If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Efficacy has not been demonstrated in improvement of migraine-associated symptoms (eg, phonophobia, nausea, photophobia) in patients aged 12-17 years (Linder, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Only indicated for treatment of acute migraine; it is not indicated for migraine prophylaxis, or for the treatment of cluster headaches, hemiplegic migraine, or basilar migraine. If a patient does not respond to the first dose, the diagnosis of acute migraine should be reconsidered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F131864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Almotriptan. Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Use in pregnancy should be limited to situations where benefit outweighs risk to fetus. In some (but not all) animal studies, administration was associated with embryolethality, fetal malformations, and decreased pup weight.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F131851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F131830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Axert Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25 mg (6): $210.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (12): $421.01",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F131831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Almogran (AT, BE, CH, DE, DK, ES, FI, FR, GB, IE, IS, IT, JP, KP, NL, NO, PT, SE);",
"     </li>",
"     <li>",
"      Amignul (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~180-200 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via MAO type A oxidative deamination (~27% of dose) and CYP3A4 and 2D6 (~12% of dose) to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~75%; ~40% of total dose as unchanged drug); feces (~13% of total dose as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(11):1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/26/20901/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen LC and Ashcroft DM, &ldquo;Meta-Analysis Examining the Efficacy and Safety of Almotriptan in the Acute Treatment of Migraine,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2007, 47(8):1169-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/26/20901/abstract-text/17883521/pubmed\" id=\"17883521\" target=\"_blank\">",
"        17883521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freitag F, Smith T, Mathew N, et al, &ldquo;Effect of Early Intervention With Almotriptan vs. Placebo on Migraine-Associated Functional Disability: Results from the AEGIS Trial,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2008, 48(3):341-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/26/20901/abstract-text/18302700/pubmed\" id=\"18302700\" target=\"_blank\">",
"        18302700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goadsby PJ, Zanchin G, Geraud G, et al, &ldquo;Early vs. Non-Early Intervention in Acute Migraine&mdash;&lsquo;Act when Mild (AwM)'. A Double-Blind, Placebo-Controlled Trial of Almotriptan,&rdquo;",
"      <i>",
"       Cephalalgia",
"      </i>",
"      , 2008, 28(4):383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/26/20901/abstract-text/18294251/pubmed\" id=\"18294251\" target=\"_blank\">",
"        18294251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linder SL, Mathew NT, Cady RK, et al, &ldquo;Efficacy and Tolerability of Almotriptan in Adolescents: A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2008, 48(9):1326-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/26/20901/abstract-text/18484981/pubmed\" id=\"18484981\" target=\"_blank\">",
"        18484981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathew NT, Finlayson G, Smith TR, et al, &ldquo;Early Intervention With Almotriptan: Results of the AEGIS Trial (AXERT&reg; Early Migraine Intervention Study),&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2007, 47(2):189-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/26/20901/abstract-text/17300358/pubmed\" id=\"17300358\" target=\"_blank\">",
"        17300358",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazzoleni R, Kreisler A, Lucas C, et al, &ldquo;Seizure After Use of Almotriptan,&rdquo;",
"      <i>",
"       Clin NeurolNeurosurg",
"      </i>",
"      , 2008, 110(8):850-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/26/20901/abstract-text/18599194/pubmed\" id=\"18599194\" target=\"_blank\">",
"        18599194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McEnroe JD and Fleishaker JC, &ldquo;Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT1B/1DReceptor Agonist for the Treatment of Migraine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2005, 44(3):237-46.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8919 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.243-7F1A92C927-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20901=[""].join("\n");
var outline_f20_26_20901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131843\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131844\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131870\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131846\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7827063\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131847\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131848\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131849\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131822\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131809\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9405718\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131823\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131878\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131868\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131827\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131813\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131864\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131817\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131819\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131829\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131851\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131830\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570475\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131831\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131812\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131826\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8919|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/4/22597?source=related_link\">",
"      Almotriptan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/40/32388?source=related_link\">",
"      Almotriptan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_26_20902="Growing pains";
var content_f20_26_20902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growing pains",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20902/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20902/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20902/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20902/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20902/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20902/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/26/20902/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent, self-limited extremity pains for which the parents, child, and health care provider have no explanation are often called \"growing pains.\" Such pains were first described in the medical literature in 1823 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent publications attributed these pains to \"rheumatism,\" a word synonymous with rheumatic fever at the time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. Correlations were described with digestive and sleep disorders, loose joints, poor posture, and chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. By the 1930s and 1940s, growing pains were distinguished from rheumatic fever and other pathologic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This distinction remains the focus of the evaluation of children with recurrent limb pain.",
"   </p>",
"   <p>",
"    Growing pains are benign, and usually resolve within a year or two of onset. They must be distinguished from pathologic causes of pain that require additional therapy (",
"    <a class=\"graphic graphic_table graphicRef59384 \" href=\"UTD.htm?9/46/9965\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The epidemiology, etiology, clinical features, evaluation, and management of growing pains in children are reviewed here. The evaluation of children with joint pain and limp is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=see_link\">",
"     \"Approach to the child with a limp\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=see_link\">",
"     \"Evaluation of the child with joint pain or swelling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus definition of growing pains and as a result there are no specific inclusion or exclusion criteria that are uniformly applied to studies of children with complaints of growing pains. The key consideration is that clinicians not dismiss as \"growing pains\" a significant problem for which intervention may be appropriate.",
"   </p>",
"   <p>",
"    In this regard, it is best to restrict \"growing pains\" to the description of children with pain awakening them at night (or from naps) who are otherwise without any manifestation of musculoskeletal problems. In contrast, children with unexplained joint pains that occur in association with activity deserve further investigation, which the child with typical \"growing pains\" may not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growing pains usually begin between 2 and 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/10\">",
"     10",
"    </a>",
"    ]. The prevalence varies from 4 to 37 percent depending upon the population studied, the age of the children, and the clinical definition used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/2,11-14\">",
"     2,11-14",
"    </a>",
"    ]. However, surveys of schoolchildren indicate that as many as 10 to 20 percent have had growing pains [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Growing pains are slightly more common among girls than boys [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/11-13,18\">",
"     11-13,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of growing pains is not known. Although they occur in growing children, they are not actually caused by growth. Growing pains do not coincide with periods of rapid growth, do not occur at the sites of growth, and do not affect the growth of children who have them [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Emotional disturbance and psychogenic illness often are mentioned as possible causes, but have not been studied systematically.",
"   </p>",
"   <p>",
"    Several other etiologies have been proposed, including fatigue, mild orthopedic and postural abnormalities, restless leg syndrome, and local overuse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Parents of children with growing pains often reveal a pattern of increased complaints following an increased level of physical activity. A study of bone speed of sound (SOS) measured by quantitative ultrasonography provides support for local overuse as a contributing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/23\">",
"     23",
"    </a>",
"    ]. In this study, children with growing pains had decreased SOS compared to control children. Decreased SOS is also seen in patients with local overuse.",
"   </p>",
"   <p>",
"    In population-based studies, growing pains are consistently associated with other recurrent pains (eg, headache and abdominal pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/13,18,24-26\">",
"     13,18,24-26",
"    </a>",
"    ]. In one study, children with recurrent headache (45 percent of whom also had growing pains) were more often described by their parents as having greater sensitivity to pain, greater reaction to stressful situations, and more depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/24\">",
"     24",
"    </a>",
"    ]. In another study, children with growing pains were found to have a decreased pain threshold compared to control children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=see_link\">",
"     \"Tension-type headache in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of growing pains have been described in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/11-13,18,28\">",
"     11-13,18,28",
"    </a>",
"    ]. Each of these studies had different inclusion criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 721 school children, cases of growing pains (4.2 percent) were defined by pain of &ge;3 months' duration, pain severe enough to interrupt normal activity, including sleep, and pain not specifically related to the joints [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 257 6 to 7 year olds and 419 10 to 11 year olds, children were identified by their parents (13.6 percent of 6 to 7 year olds and 19.8 percent of 10 to 11 year olds) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study of 2178 children between 6 and 19 years of age, cases of growing pains (18.4 and 12.5 percent of girls and boys, respectively) were defined by intermittent and frequently incapacitating pain of the legs (and sometimes arms) that resolved by morning and was not accompanied by objective changes on physical examination [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the varying case definitions, certain common clinical features emerge, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/11-13,15,16,18,29,30\">",
"     11-13,15,16,18,29,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growing pains occur most commonly in preschool and school-aged children.",
"     </li>",
"     <li>",
"      Pain occurs primarily in the lower extremities; upper extremity pain occurs, but only in conjunction with lower extremity pain.",
"     </li>",
"     <li>",
"      Pain is bilateral and located deep in the legs, usually the thigh or calf.",
"     </li>",
"     <li>",
"      Pain is paroxysmal, and may be severe enough to make the child weep; symptom-free periods of days, weeks, or months occur between episodes.",
"     </li>",
"     <li>",
"      In older children (6 to 12 years), the pain may be described as crampy, a creeping sensation, or restless legs [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pain occurs primarily in the evening or nighttime hours and may interrupt sleep; it usually resolves by morning, but some patients have isolated daytime complaints.",
"     </li>",
"     <li>",
"      Pain is relieved by massage, heat, or first-order analgesics, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Normal patterns of activity are maintained.",
"     </li>",
"     <li>",
"      The physical examination during and after the episodes is normal.",
"     </li>",
"     <li>",
"      Associated complaints of recurrent abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      headaches occur in approximately one-third of patients.",
"     </li>",
"     <li>",
"      A family history of growing pains or rheumatic complaints is common.",
"     </li>",
"     <li>",
"      The pains are chronic, but episodic, with an overall duration that often may last years and persist into adolescence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a typical presentation in an otherwise healthy child who remains pain free during the day, the diagnosis can usually be made clinically. It is not necessary to perform radiographs or laboratory tests to make the diagnosis in these children.",
"   </p>",
"   <p>",
"    The usually accepted criteria for growing pains include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/11,31\">",
"     11,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain typically occurs late in the day or awakens the child.",
"     </li>",
"     <li>",
"      Pain must be severe enough to interrupt normal activity, including sleep.",
"     </li>",
"     <li>",
"      Pain is not specifically related to the joints.",
"     </li>",
"     <li>",
"      Pain occurs at least monthly for at least three months.",
"     </li>",
"     <li>",
"      Pain is intermittent, with symptom-free periods of at least days.",
"     </li>",
"     <li>",
"      Pain is accentuated by increased activity during the day [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The physical examination is normal.",
"     </li>",
"     <li>",
"      Ancillary studies, if performed, are normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of intermittent lower extremity pain is extensive (",
"    <a class=\"graphic graphic_table graphicRef59384 \" href=\"UTD.htm?9/46/9965\">",
"     table 1",
"    </a>",
"    ). It is important to exclude conditions that may require additional evaluation, therapy, or monitoring. These conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trauma (particularly overuse syndromes and stress fractures)",
"     </li>",
"     <li>",
"      Tumors of the blood or bone",
"     </li>",
"     <li>",
"      Infection (particularly if partially treated with antibiotics)",
"     </li>",
"     <li>",
"      Osteonecrosis (eg, Legg-Calv&eacute;-Perthes disease)",
"     </li>",
"     <li>",
"      Metabolic disorders (eg, rickets)",
"     </li>",
"     <li>",
"      Sickle cell anemia",
"     </li>",
"     <li>",
"      Vascular insufficiency",
"     </li>",
"     <li>",
"      Rheumatologic disorders (particularly spondyloarthropathies, such as psoriatic arthritis and reactive arthritis, which may cause nighttime pain)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these disorders can be excluded on the basis of history and physical examination. Laboratory studies and or radiographs may be necessary in others. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tumors, particularly bone tumors, may be the most difficult to distinguish from growing pains without additional studies because tumor pain often occurs at night.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone tumors &mdash; The pain associated with primary bone tumors typically begins as intermittent pain and increases in severity over the course of time. The pain associated with Ewing sarcoma, though, may disappear spontaneously for weeks or months at a time. In contrast to growing pains that are bilateral, the bone pain associated with tumors is unilateral. Patients with bone tumors also may have a palpable mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"       \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Osteoid osteomas are benign tumors. They may present with pain in one lower extremity, which is intermittent and worse at night. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of benign bone tumors in children and adolescents\", section on 'Osteoid osteoma'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      On physical examination, children with bone tumors will experience tenderness with compression of the bone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      soft tissue, which is not seen in children with growing pains.",
"     </li>",
"     <li>",
"      Leukemia &mdash; Children with leukemia usually have systemic symptoms, such as fever, pallor, or weight loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"       \"Clinical assessment of the child with suspected cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of children who complain of recurrent, self-limited lower extremity pain should include a complete history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should characterize the pain episodes and include the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How often does it occur?",
"     </li>",
"     <li>",
"      Where does it occur?",
"     </li>",
"     <li>",
"      When does it occur? How long does it last?",
"     </li>",
"     <li>",
"      What makes it better?",
"     </li>",
"     <li>",
"      Does the pain affect the child's activity, sleep, or school attendance?",
"     </li>",
"     <li>",
"      Are there any associated signs or symptoms (eg, fever, swelling, erythema, malaise, weight loss)?",
"     </li>",
"     <li>",
"      Does the child have recurrent headaches or abdominal pain?",
"     </li>",
"     <li>",
"      Is there a history of recent illness (eg, viral infection, Group A streptococcal infection)?",
"     </li>",
"     <li>",
"      Has there been a recent increase or change in type of exercise or sports activity?",
"     </li>",
"     <li>",
"      Is there a family history of medical problems (eg, sickle cell anemia, metabolic disease, rheumatologic disorders)?",
"     </li>",
"     <li>",
"      Is there a family history of growing pains?",
"     </li>",
"     <li>",
"      Is there the complaint of pain in the night (or naps) or during the day? (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, it is important to determine whether the child is receiving any \"secondary gain\" from the pain episodes. One must also consider the possibility of child abuse (physical or emotional), however, abused children rarely restrict their complaints to the night time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What are the current stressors facing the patient and family?",
"     </li>",
"     <li>",
"      Do the episodes of pain correlate temporally with events the child may wish to avoid?",
"     </li>",
"     <li>",
"      Who might benefit if the pain prevented some activity?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination must be carefully performed to exclude other conditions in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef66815 \" href=\"UTD.htm?34/21/35163\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities on the musculoskeletal examination (eg, decreased range of motion, joint swelling, or elicited tenderness upon bone compression) may indicate orthopedic or rheumatologic conditions.",
"     </li>",
"     <li>",
"      Abnormal skin findings are sometimes present in children with rheumatologic disease or infection (eg, dermatomyositis, systemic lupus erythematosus, psoriasis, or syphilis).",
"     </li>",
"     <li>",
"      The neurologic examination, including gait, may be abnormal in children with spinal cord tumors.",
"     </li>",
"     <li>",
"      The finding of lymphadenopathy or splenomegaly should prompt consideration of malignancy, infection, or rheumatic disease.",
"     </li>",
"     <li>",
"      An abnormal gait may be seen in a variety of musculoskeletal disorders, but should not be present in a child with growing pains. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=see_link\">",
"       \"Approach to the child with a limp\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evaluation may be necessary to exclude more serious conditions in the differential diagnosis, and usually is warranted in all children who have [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/29,32,33\">",
"     29,32,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic symptoms (eg, unexplained fever, weight loss, decreased activity)",
"     </li>",
"     <li>",
"      Persistent, increasing, or unilateral limb pain",
"     </li>",
"     <li>",
"      Pain during the day",
"     </li>",
"     <li>",
"      Limp or limitation of activities",
"     </li>",
"     <li>",
"      Localized findings on examination (decreased range of motion, warmth, tenderness, swelling, erythema)",
"     </li>",
"     <li>",
"      Pain that is isolated to the upper extremity, back, or groin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The additional evaluation may include, but is not limited to, complete blood count (CBC) and differential, erythrocyte sedimentation rate (ESR) (or C reactive protein),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plain radiographs. Abnormal results in any of these tests exclude a diagnosis of growing pains.",
"   </p>",
"   <p>",
"    Pediatricians, family practitioners, pediatric orthopedic surgeons, and pediatric rheumatologists were surveyed regarding the diagnostic evaluation of a child with typical growing pains [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/33\">",
"     33",
"    </a>",
"    ]. Depending upon the specialty, between 19 and 51 percent of clinicians would order CBC and differential, between 30 and 58 percent would order an ESR, and 37 to 52 percent would order radiographs. Diagnostic tests were more likely to be ordered if the patient was &gt;12 years of age, or if the clinician felt the need to reassure the parents.",
"   </p>",
"   <p>",
"    While parental concern is not always a reliable indicator of disease, it is easily assessed during the office visit. When parents seem particularly concerned and difficult to reassure, thorough diagnostic evaluation is an effective way to both exclude a significant underlying problem and provide the necessary reassurance. However, the evaluation must be clinically appropriate, since there is potentially no limit to the concerns that families may express, or the studies they may request. Clinicians who are confident of their diagnosis can usually reassure reasonable families of the appropriateness of their recommendations, even without an extensive diagnostic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is written about the treatment of growing pains in children, and few controlled trials have been performed. The management must include recognition of the child's pain and its effects on his or her functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/34\">",
"     34",
"    </a>",
"    ]. Education of the patient and family is a crucial component of the management plan. An understanding of the benign nature of the disorder may alleviate unnecessary concern, fear, and suffering [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute pain relief may be achieved with massage, analgesics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ), and heat in various forms. Often episodes which awaken the child at night cluster in groups of nights and follow days of increased physical activity. In a child who has been appropriately evaluated, acetaminophen or ibuprofen given at bed time may prevent awakening following a day of increased activities or break the cycle of repeated complaints. At times, a longer acting analgesic given after dinner, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/61/27608?source=see_link\">",
"     naproxen",
"    </a>",
"    , may be needed for the child to be able to sleep through the night. However, none of these medications should be continued beyond a few days.",
"   </p>",
"   <p>",
"    The pain should not be allowed to interfere with usual childhood activities and social experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/31\">",
"     31",
"    </a>",
"    ]. Discontinuation of normal activities does not prevent growing pains, and may in fact make the pain a focus for the child and family.",
"   </p>",
"   <p>",
"    Muscle stretching exercises may relieve chronic symptoms. In one unblinded study of 36 children with growing pains, children who were treated with a muscle stretching regimen (",
"    <a class=\"graphic graphic_table graphicRef66815 \" href=\"UTD.htm?34/21/35163\">",
"     table 2",
"    </a>",
"    ) had more rapid resolution of their symptoms than controls (average of zero episodes per month at 9 months versus 1 to 2 episodes per month at 18 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20902/abstract/20\">",
"     20",
"    </a>",
"    ]. However, it is not clear whether the improvement was a result of the exercise or the increased parental attention required for the twice-daily routine.",
"   </p>",
"   <p>",
"    The author provides education and reassurance for children who are having growing pains fewer than three to four times per week. He treats children who have more than four episodes of pain per week prophylactically.",
"   </p>",
"   <p>",
"    The child should be seen in follow-up at periodic intervals to evaluate the course of the disease. Children who have pain that increases in frequency or severity may require additional evaluation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Further evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growing pains are defined as pain awakening a child at night (or from naps) who is otherwise without any manifestation of musculoskeletal problems. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although growing pains are a common musculoskeletal condition, occurring in approximately 15 percent of children, their etiology is not known. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important that appropriate evaluation is performed to differentiate growing pains from other more serious conditions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the child appears ill, complains of pain during the day or with activity, or if pain worsens or persists, the diagnosis is unlikely to be growing pains. A thorough evaluation (eg, complete blood count and differential, erythrocyte sedimentation rate or C reactive protein,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plain radiographs) is required in children who meet any of these conditions. Abnormal results in any of these tests exclude a diagnosis of growing pains. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is usually symptomatic, and must include education and reassurance.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Duchamp M. Malodies de la croissance. In: Memoires de Medecine Practique, Levrault FG, Lobstein JF (Eds), Paris 1823.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/2\">",
"      Hawksley JC. Race, Rheumatism and Growing Pains. Arch Dis Child 1931; 6:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/3\">",
"      Seham M, Hilbert EH. Muscular rheumatism. Am J Dis Child 1933; 46:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/4\">",
"      Hawksley JC. The incidence and significance of growing pains in children and adolescents. J Roy Inst Pub Health 1938; 1:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/5\">",
"      Shapiro MJ. The differential diagnosis of nonrheumatic growing pains and subacute rheumatic fever. J Pediatr 1939; 14:315.",
"     </a>",
"    </li>",
"    <li>",
"     Sheldon W. Diseases of infancy and childhood, 5th ed, JA Churchill, London 1946.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/7\">",
"      Hawksley JC. Growing Pains in Relation to Rheumatism. Br Med J 1939; 1:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/8\">",
"      Bennie PB. Growing pains. Arch Pediatr 1894; 6:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/9\">",
"      Brown LT. Growing pains. A possible mechanical explanation. Boston Med Surg J 1910; 162:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/10\">",
"      Szer I. Are those limb pains \"growing\" pains. Contemp Pediatr 1989; 6:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/11\">",
"      NAISH JM, APLEY J. \"Growing pains\": a clinical study of non-arthritic limb pains in children. Arch Dis Child 1951; 26:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/12\">",
"      Brenning R. Growing pains. Acta Soc Med Upsala 1960; 65:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/13\">",
"      Oster J. Recurrent abdominal pain, headache and limb pains in children and adolescents. Pediatrics 1972; 50:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/14\">",
"      Evans AM, Scutter SD. Prevalence of \"growing pains\" in young children. J Pediatr 2004; 145:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/15\">",
"      Oster J, Nielsen A. Growing pains. A clinical investigation of a school population. Acta Paediatr Scand 1972; 61:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/16\">",
"      Peterson H. Growing pains. Pediatr Clin North Am 1986; 33:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/17\">",
"      Brady M, Grey M. Growing pains: a myth or a reality. J Pediatr Health Care 1989; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/18\">",
"      Abu-Arafeh I, Russell G. Recurrent limb pain in schoolchildren. Arch Dis Child 1996; 74:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/19\">",
"      Growing pains. Br Med J 1972; 3:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/20\">",
"      Baxter MP, Dulberg C. \"Growing pains\" in childhood--a proposal for treatment. J Pediatr Orthop 1988; 8:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/21\">",
"      Manners P. Are growing pains a myth? Aust Fam Physician 1999; 28:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/22\">",
"      Oster J. Growing pain. A symptom and its significance. (A review). Dan Med Bull 1972; 19:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/23\">",
"      Friedland O, Hashkes PJ, Jaber L, et al. Decreased bone speed of sound in children with growing pains measured by quantitative ultrasound. J Rheumatol 2005; 32:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/24\">",
"      Aromaa M, Sillanp&auml;&auml; M, Rautava P, Helenius H. Pain experience of children with headache and their families: A controlled study. Pediatrics 2000; 106:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/25\">",
"      Lavigne JV, Schulein MJ, Hahn YS. Psychological aspects of painful medical conditions in children. II. Personality factors, family characteristics and treatment. Pain 1986; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/26\">",
"      Oberklaid F, Amos D, Liu C, et al. \"Growing pains\": clinical and behavioral correlates in a community sample. J Dev Behav Pediatr 1997; 18:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/27\">",
"      Hashkes PJ, Friedland O, Jaber L, et al. Decreased pain threshold in children with growing pains. J Rheumatol 2004; 31:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/28\">",
"      Pavone V, Lionetti E, Gargano V, et al. Growing pains: a study of 30 cases and a review of the literature. J Pediatr Orthop 2011; 31:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/29\">",
"      Halliwell P, Monsell F. Growing pains: a diagnosis of exclusion. Practitioner 2001; 245:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/30\">",
"      Atar D, Lehman WB, Grant AD. Growing pains. Orthop Rev 1991; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     Frazer CH, Rappaport LA. Recurrent pains. In: Developmental behavioral pediatrics, 3rd ed, Levine MD, Carey WB, Crocker AC (Eds), WB Saunders, Philadelphia 1999. p.357.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/32\">",
"      Cassidy JT. Progress in diagnosis and understanding chronic pain syndromes in children and adolescents. Adolesc Med 1998; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/33\">",
"      Macarthur C, Wright JG, Srivastava R, et al. Variability in physicians' reported ordering and perceived reassurance value of diagnostic tests in children with 'growing pains'. Arch Pediatr Adolesc Med 1996; 150:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/34\">",
"      American Academy of Pediatrics. Committee on Psychosocial Aspects of Child and Family Health, Task Force on Pain in Infants, Children, and Adolescents. The assessment and management of acute pain in infants, children, and adolescents. Pediatrics 2001; 108:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20902/abstract/35\">",
"      Cassel EJ. The nature of suffering and the goals of medicine. N Engl J Med 1982; 306:639.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6431 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20902=[""].join("\n");
var outline_f20_26_20902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6431|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/46/9965\" title=\"table 1\">",
"      DDx growing pains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/21/35163\" title=\"table 2\">",
"      Exercise Rx growing pains",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=related_link\">",
"      Approach to the child with a limp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=related_link\">",
"      Evaluation of the child with joint pain or swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=related_link\">",
"      Tension-type headache in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_26_20903="Screening for inherited thrombophilia in asymptomatic populations";
var content_f20_26_20903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for inherited thrombophilia in asymptomatic populations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20903/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20903/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20903/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20903/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20903/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/26/20903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. Factor V Leiden is the most common cause of the syndrome accounting for 40 to 50 percent of cases. The prothrombin gene mutation, deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The total incidence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with about 10 percent in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will discuss the usefulness of screening for these conditions in various asymptomatic populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The diagnostic approach to the patient presenting with thrombosis and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL SCREENING ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening techniques are used clinically to identify individuals at risk for a preventable disease or complication. Reliable assays are now available to test for the presence of the various causes of inherited thrombophilia (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"UTD.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, unselected population-based screening for inherited thrombophilia is not recommended because of three salient factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The low frequency of the symptomatic condition in the general population",
"     </li>",
"     <li>",
"      The low penetrance of the symptomatic condition among carriers of the most common thrombophilic conditions (eg, factor V Leiden and prothrombin G20210A mutations),",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      The lack of a safe, cost-effective, long-term method of prophylaxis if an abnormality is found.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a family history of thrombosis are at increased risk for a mutation. However, a simple positive history is not a reliable criterion to select patients for screening. This was illustrated in a report of 101 patients who had their first and single thromboembolic event while using oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/5\">",
"     5",
"    </a>",
"    ]. A family history of thrombosis in a first-degree relative had a positive predictive value of only 14 percent for factor V Leiden.",
"   </p>",
"   <p>",
"    The usefulness of screening for hereditary thrombophilia has been considered in family members of patients with a history of VTE and a thrombophilic defect, especially antithrombin, protein S, or protein C deficiencies. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 150 pedigrees with factor V Leiden or antithrombin, protein C, or protein S deficiency, the lifetime probability of developing thrombosis compared with those with no defect was 8.5 times higher for carriers of protein S deficiency, 8.1 for antithrombin deficiency, 7.3 for protein C deficiency, and 2.2 for carriers of factor V Leiden [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/6\">",
"       6",
"      </a>",
"      ]. Similar conclusions were reached in a systematic literature review that did not include this study [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective cohort study of 2479 relatives of individuals with thrombosis and a thrombophilic defect found that relatives who shared an inherited defect in protein S, protein C, or antithrombin had an annual risk of VTE of 1.5 to 1.9 percent and a cumulative VTE incidence of 55 percent at 10 years; individuals who shared other thrombophilic defects with the index case had lower cumulative risks (eg, 7 percent for factor V Leiden and 11 percent for prothrombin mutations) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective observational study of 206 pediatric patients &lt;18 years, found that 27 percent of first and second degree relatives had an inherited thrombophilia, the most common of which was heterozygosity for the factor V Leiden mutation (57 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/9\">",
"       9",
"      </a>",
"      ]. Of these relatives with inherited thrombophilia, 23 percent (33 of 146) had VTE. In contrast, only 3.6 percent of relatives without an inherited defect had VTE. The risk of clinically important thrombophilia was greatest in individuals with protein S, protein C, and antithrombin mutations and least with factor V Leiden mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the genetic pattern for the inherited thrombophilias is autosomal dominant, one-half of the relatives of each patient with thrombosis and hereditary thrombophilia will carry the same defect. However, the value of screening for the presence of a defect remains controversial. The following sections provide arguments for and against such screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Arguments against screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification via screening of an inherited thrombophilia would theoretically permit the institution of prophylactic anticoagulation, either permanently or during high-risk situations. However, there are no data that justify the risks of long-term or permanent prophylactic anticoagulation in the asymptomatic patient.",
"   </p>",
"   <p>",
"    As examples, two studies of the incidence of thromboembolic disease in family members of patients with factor V Leiden suggest that neither of these strategies would be of value [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In a retrospective, blinded analysis, the incidence of venous thromboembolism was assessed in 437 first-degree relatives of 112 symptomatic heterozygotes and 30 relatives of six homozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/10\">",
"     10",
"    </a>",
"    ]. The annual incidence of thromboembolism in relatives of heterozygous patients was 0.45 percent in those with the mutation and 0.1 percent in those without the mutation; 20 percent of the episodes were related to surgery and 30 percent to pregnancy or the use of oral contraceptives.",
"   </p>",
"   <p>",
"    The 0.35 percent difference between the two groups suggests that approximately 300 women would have to be treated (and suffer the risks and problems of anticoagulation) in an attempt to prevent one episode of venous thromboembolism per year. This absolute benefit does not appear to justify life-long anticoagulation. It was also estimated that, if all identified pregnant carriers were treated with anticoagulant prophylaxis, treatment would be given unnecessarily in 98 percent of pregnant carriers who would be exposed to the risks of bleeding, bone loss, and thrombocytopenia. Similarly, if all potential users of oral contraceptives were screened and then discouraged from use of the drugs if they tested positive, 333 women would be identified for every episode of venous thromboembolism prevented.",
"   </p>",
"   <p>",
"    Similar arguments against screening for the prothrombin G20210A mutation have been presented, in which the annual incidence of thromboembolism in relatives of heterozygous patients was 0.37 percent in those with the mutation and 0.12 percent in those without the mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arguments in favor of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although prophylactic anticoagulation in the asymptomatic patient cannot be universally justified, there are certain potential high-risk situations (eg, major surgery, trauma, immobilization for &gt;7 days, pregnancy and puerperium) which can be identified by screening of relatives and which may prompt consideration of prophylactic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, individuals can be educated about precautions and early symptoms. As an example, women can be made aware of the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio associated with oral contraceptives and hormone replacement therapy and make more informed decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/15\">",
"     15",
"    </a>",
"    ]. This applies particularly to individuals who are heterozygous for protein C, protein S, and antithrombin deficiency, conditions that appear to have a three- to fourfold higher thrombosis risk than heterozygous factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING FOR SPECIFIC INHERITED THROMBOPHILIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23302957\">",
"    <span class=\"h2\">",
"     Factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor V Leiden is the most common inherited thrombophilia. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Homozygosity and multiple defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, an asymptomatic high risk homozygote with the factor V Leiden or prothrombin G20210A mutation can be diagnosed by family screening. Infrequently, a second hereditary defect, particularly factor V Leiden, is identified in a patient with one of the other inherited thrombophilic defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carriers of two defects seem to be at a higher risk for thrombosis than their relatives with a single defect. In one review of four studies, approximately 75 percent of the family members who were carriers of two defects had experienced thrombosis compared with 10 to 30 percent of the carriers of a single defect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these data may reflect an artificially elevated risk based on reporting bias. &nbsp;",
"   </p>",
"   <p>",
"    Management of individuals with homozygosity or compound heterozygosity for inherited thrombophilias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of inherited thrombophilia\", section on 'Argument against long-term therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of inherited thrombophilia\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link&amp;anchor=H7898355#H7898355\">",
"     \"Inherited thrombophilias in pregnancy\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Protein C deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with protein C deficiency are at potential risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis and should be aware of this diagnosis, if present. In a patient with thrombosis who is known to be protein C deficient, oral anticoagulation should be started under the cover of full heparinization. If used, the dose of warfarin should be increased gradually, starting from a relatively low dose (eg, 2",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H13#H13\">",
"     \"Protein C deficiency\", section on 'Warfarin-induced skin necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antithrombin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with hereditary antithrombin (formerly called antithrombin III) deficiency have an unusually high risk for thromboembolism. One study, for example, evaluated 78 women with inherited deficiency in antithrombin, protein S, or protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/17\">",
"     17",
"    </a>",
"    ]. Deep vein thrombosis occurred in 18 percent of patients with type I antithrombin deficiency during pregnancy and in 33 percent in the postpartum period. By comparison, thrombosis during pregnancy occurred in only 7 percent of patients with protein C deficiency and in none of the patients with protein S deficiency. Thrombosis in the postpartum period occurred in 19 percent of protein C and 17 percent of protein S deficient patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, women with antithrombin deficiency should receive anticoagulant prophylaxis with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH)",
"    <strong>",
"     throughout",
"    </strong>",
"    pregnancy. Obstetricians often prefer that women be transitioned to unfractionated heparin at about 36 weeks due to its shorter half-life, so that there is a greater chance that an epidural or Cesarean delivery can safely be performed if necessary. In the postpartum period, either LMWH or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be administered for 6 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Homocysteine and the MTHFR variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clinical rationale for measurement of plasma homocysteine levels or for assaying for presence of the MTHFR 677C&mdash;&gt;T variant when screening for the risk of VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of homocysteine\", section on 'Screening for hyperhomocysteinemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Screening for hyperhomocysteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that the benefits of screening are likely to be significant in the asymptomatic family member with thrombophilia",
"    <strong>",
"     only",
"    </strong>",
"    if there is a strong family history of VTE (ie, multiple first-degree relatives with thrombotic events prior to age 50) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/8\">",
"     8",
"    </a>",
"    ]. Following an informed discussion with such patients with VTE and thrombophilia, we recommend screening first-degree family members for the identified defect. How this should be performed is discussed separately. We do not recommend screening for high homocysteine levels or presence of the MTHFR variant in any setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H25#H25\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Choice of coagulation tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In VTE patients with thrombophilia and no family history, the benefit of screening first-degree family members is not established. An individualized approach should be taken to testing such individuals after discussing the potential benefits and risks and taking personal preference into account.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SCREENING IN HIGH RISK SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically do not screen women taking oral contraceptives or considering their use for inherited thrombophilia unless a blood relative has inherited thrombophilia and clinical thromboembolic disease. Of an estimated 9.9 million American women using oral contraceptives (OCs), approximately 423,000 are likely to carry the factor V Leiden mutation. The carrier rate is highest in Caucasian women (5.3 percent) and much lower in African American (1.2 percent) and Asian American (0.5 percent) women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/18\">",
"     18",
"    </a>",
"    ]. In young women, both the incidence rate of venous thromboembolism (VTE, two events per 10,000 person years) and the estimated mortality rate from pulmonary embolism (six events per 100,000 years) are low enough that the number of women required for screening to prevent one death is excessively large (approximately 400,000) and the costs excessive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, routine screening is generally not recommended in the absence of a history of a family member with thrombosis in association with an inherited thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/3,5,18-22\">",
"     3,5,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among women with a history of thrombosis associated with OCs, it might appear reasonable to screen because of the increased risk of a first VTE in association with inherited thrombophilia. Most physicians, however, would not advise continuing or restarting OCs after a thrombotic episode in any case. After the discontinuation of anticoagulation, the absolute annual recurrence risk in such women is generally quite low, save for high-risk situations, at which time thromboprophylaxis should be administered.",
"   </p>",
"   <p>",
"    Among women with a family history of multiple thromboses, particularly at a younger age, clinical wisdom dictates extreme caution in the use of OCs. The detection of a single or multiple genetic defects with screening might provide information that is helpful in making this decision [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/19,23,24\">",
"     19,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not consider OCs to be absolutely contraindicated in asymptomatic women who are heterozygous for factor V Leiden but tend to discourage their use. The benefits and risks of different types of contraceptives need to be considered along with patient preference. Accordingly, we inform such women of the small absolute increase in the risk of VTE if estrogen-progestin OCs are used, along with the higher absolute increase in the risk of VTE if OCs are not used and there is an unintended pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. For such women, we suggest use of nonhormonal or progestin-only contraceptive methods rather than estrogen-progestin methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=see_link&amp;anchor=H5#H5\">",
"     \"Contraception for women with inherited thrombophilias\", section on 'Progestin-only methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall maternal death rate due to pulmonary embolism in the United States is estimated at 1.2 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/26\">",
"     26",
"    </a>",
"    ]. In a study of over 72,000 deliveries, the incidence of deep vein thrombosis alone was much higher at 71 per 100,000 deliveries; factor V Leiden accounted for 8 percent of the patients with thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/27\">",
"     27",
"    </a>",
"    ]. If one-half of the fatal pulmonary emboli were to occur in the 10 percent of women with factor V Leiden, the risk would be approximately 1 in 13,000. This is lower than the risk of fatal bleeding or intracranial bleeding that leads to lifelong handicap [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/19\">",
"     19",
"    </a>",
"    ]; the latter risk has been estimated at about 0.5 patients per 100 treatment years or 1 in 2000 mothers anticoagulated for at least six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, screening all pregnant women for an inherited thrombophilia is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/19,29\">",
"     19,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Obstetric complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to an association with venous thrombosis, inherited thrombophilia has also been linked to obstetric complications such as second and third trimester fetal loss, which are associated with intervillous or spiral artery thrombosis and inadequate placental perfusion. The value of screening women with one of these complications is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20903/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"       \"Patient information: Factor V Leiden (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15692258\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited thrombophilia is a genetic tendency to venous thromboembolism (VTE). Common causes include Factor V Leiden (the most common condition), the prothrombin gene mutation, and deficiencies in protein S, protein C, and antithrombin.",
"     </li>",
"     <li>",
"      Unselected population-based screening for inherited thrombophilic states is not recommended because of their low frequency, low penetrance, and lack of a safe, cost-effective, long-term method of prophylaxis if an abnormality is found. Specifically, there are no data that justify the risks of prophylactic anticoagulation in the asymptomatic patient with inherited thrombophilia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Arguments against screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefits of screening are likely to be significant in the asymptomatic family member with thrombophilia",
"      <strong>",
"       only",
"      </strong>",
"      if there is a strong family history of VTE (ie, multiple first-degree relatives with thrombotic events prior to age 50); such histories are more common in patients with deficiencies of antithrombin, protein C, or protein S. However, in certain high thrombotic risk situations (eg, major surgery, trauma, immobilization for &gt;7 days, pregnancy and puerperium), screening for inherited thrombophilia, if present, may prompt consideration of prophylactic treatment or alteration in the",
"      <span class=\"nowrap\">",
"       type/duration",
"      </span>",
"      of antithrombotic prophylaxis. These scenarios include (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening for specific inherited thrombophilias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Screening in high risk situations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Presence of homozygosity for the Factor V Leiden or prothrombin gene mutations or multiple thrombophilic defects",
"     </li>",
"     <li>",
"      Initiation of vitamin K antagonists in patients with protein C deficiency given potential for the rare complication of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis",
"     </li>",
"     <li>",
"      Consideration of antithrombin concentrate administration in antithrombin deficiency in the peri-partum period in pregnant women or in conjunction with surgical procedures when anticoagulants cannot be safely administered (eg, during delivery or immediately following neurosurgery or spinal surgery)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In asymptomatic thrombophilic first-degree female relatives of symptomatic propositi, the use of estrogen-containing oral contraceptives or hormone-replacement therapy is discouraged.",
"     </li>",
"     <li>",
"      Management of individuals with inherited thrombophilia is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"       \"Management of inherited thrombophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/1\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/2\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/3\">",
"      Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/4\">",
"      Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/5\">",
"      Schambeck CM, Schwender S, Haubitz I, et al. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 1997; 78:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/6\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/7\">",
"      Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost 2003; 90:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/8\">",
"      Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113:5314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/9\">",
"      Holzhauer S, Goldenberg NA, Junker R, et al. Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembolism: an observational study. Blood 2012; 120:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/10\">",
"      Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/11\">",
"      Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/12\">",
"      Coppens M, van de Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006; 108:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/13\">",
"      Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/14\">",
"      Mahmoodi BK, Brouwer JL, Ten Kate MK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost 2010; 8:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/15\">",
"      Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001; 98:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/16\">",
"      Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/17\">",
"      Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/18\">",
"      Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/19\">",
"      Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/20\">",
"      de Moerloose P, Bounameaux HR, Mannucci PM. Screening test for thrombophilic patients: which tests, for which patient, by whom, when, and why? Semin Thromb Hemost 1998; 24:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/21\">",
"      Grody WW, Griffin JH, Taylor AK, et al. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/22\">",
"      Cosmi B, Legnani C, Bernardi F, et al. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med 2003; 163:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/23\">",
"      van Vlijmen EF, Brouwer JL, Veeger NJ, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/24\">",
"      Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/25\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/26\">",
"      Sachs BP, Brown DA, Driscoll SG, et al. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med 1987; 316:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/27\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/28\">",
"      van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Bri&euml;t E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/29\">",
"      Rouse DJ, Goldenberg RL, Wenstrom KD. Antenatal screening for factor V Leiden mutation: a critical appraisal. Obstet Gynecol 1997; 90:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20903/abstract/30\">",
"      Sibai BM. Thrombophilias and adverse outcomes of pregnancy--what should a clinician do? N Engl J Med 1999; 340:50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1364 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20903=[""].join("\n");
var outline_f20_26_20903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15692258\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL SCREENING ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Arguments against screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arguments in favor of screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING FOR SPECIFIC INHERITED THROMBOPHILIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23302957\">",
"      Factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Homozygosity and multiple defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antithrombin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Homocysteine and the MTHFR variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SCREENING IN HIGH RISK SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Obstetric complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15692258\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1364\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1364|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/6/1132\" title=\"table 1\">",
"      Causes of venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26759?source=related_link\">",
"      Contraception for women with inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=related_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_26_20904="Nonalcoholic steatohepatitis with a granuloma - medium power";
var content_f20_26_20904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonalcoholic steatohepatitis with a granuloma (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In addition to fatty infiltration, there are at least two Mallory bodies, intense inflammation, and one giant cell granuloma. There was only one granuloma in a liver biopsy core that had more than 20 portal triads. The eminent hepatologist Gerard Klatskin noted over 45 years ago that isolated non caseating granulomas were not rare in liver biopsies and of no clinical importance in patients with diseases such as alcoholic steatohepatitis, viral hepatitis, and nonalcoholic fatty liver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20904=[""].join("\n");
var outline_f20_26_20904=null;
var title_f20_26_20905="Peripheral artery disease in chronic kidney disease";
var content_f20_26_20905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peripheral artery disease in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Ann M O'Hare, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20905/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20905/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/26/20905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is increasingly recognized that chronic kidney disease (CKD) is an independent risk factor for the development of generalized atherosclerosis and coronary artery disease, and is associated with a worse prognosis following cardiovascular events. Consequently, patients with CKD are at a much higher risk of morbidity and death related to cardiovascular disease than of eventually requiring renal replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lower extremity peripheral artery disease (PAD) is a significant clinical problem among patients with CKD. Traditionally, studies of the epidemiology of cardiovascular disease rarely examined this condition in the subset of patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/1-5\">",
"     1-5",
"    </a>",
"    ], and epidemiologic studies of PAD have generally not included CKD as a potential risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. However, a growing number of studies have described an association between PAD and CKD.",
"   </p>",
"   <p>",
"    This topic will focus on aspects of the epidemiology, diagnosis, and treatment of PAD relevant to individuals with CKD. CKD will refer to individuals with decreased kidney function, excluding dialysis patients and kidney transplant recipients. A review of this issue among patients with end-stage renal disease, and more detailed management recommendations for PAD in the general population are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37128?source=see_link\">",
"     \"Lower extremity peripheral artery disease in end-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on peripheral artery disease (PAD), which were produced in collaboration with major vascular medicine, vascular surgery, and interventional radiology societies do not specifically identify chronic kidney disease (CKD) as being a risk factor for PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/11\">",
"     11",
"    </a>",
"    ]. The Inter-Society Consensus for the Management of Peripheral Artery Disease (TASC-II) notes the association of renal insufficiency and PAD, suggesting it may be causal, but provides little supporting evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354921524\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAD appears to be more prevalent among patients with CKD than in the general population. To some extent, this may reflect the older age and higher prevalence of known risk factors for PAD such as dyslipidemias, diabetes, and hypertension among those with CKD; however, even after adjustment for these potential confounders, CKD is independently associated with an increased prevalence of PAD, and with the future risk for developing clinically significant PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Risk factors for PAD are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ankle-brachial index (ABI) &le;0.90 defines the presence of arterial obstruction, which is most often due to atherosclerosis (ie, PAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/15\">",
"     15",
"    </a>",
"    ]. In community cohort studies, the prevalence of an ABI &lt;0.90 ranges from &lt;5 percent to as high as 12.4 percent, being higher among older patients, smokers, and patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/7,9,16,17\">",
"     7,9,16,17",
"    </a>",
"    ]. The noninvasive diagnosis of peripheral artery disease and the definitions of ABI, toe-brachial index (TBI), and incompressibility are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a substantially higher prevalence of low ABI (&lt;0.90) among patients with a low estimated glomerular filtration rate (GFR) or those with albuminuria; the highest prevalence of PAD is among those with a low estimated GFR",
"    <strong>",
"     and",
"    </strong>",
"    albuminuria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/18-25\">",
"     18-25",
"    </a>",
"    ]. However, it is unclear from the existing literature to what extent these associations differ in patients with and without diabetes. Key studies are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among participants in the Cardiovascular Health Study, 12 and 7 percent of individuals with and without kidney dysfunction had an ABI &lt;0.90, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/19\">",
"       19",
"      </a>",
"      ]. ABI &lt;0.90 was inversely associated with serum creatinine after adjustment for a wide range of potential confounders.",
"     </li>",
"     <li>",
"      Among 2229 National Health and Nutrition Examination Survey (1999-2000) respondents &ge;40 years of age, 24 versus 4 percent of individuals with an estimated creatinine clearance &lt;60 versus &ge;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 had an ABI &lt;0.90 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 965 adults with diabetes enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA), the prevalence of an ABI &lt;0.90 was approximately 60 percent higher among those with, compared with those without, albuminuria after adjustment for a selection of potential confounders. Among 5217 participants without diabetes, there appeared to be no association between a low ABI and albuminuria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 5912 adults without diabetes enrolled in the National Health and Nutrition Examination Survey 1999-2004, PAD (defined as an ABI &lt;0.90 or &gt;1.40) was independently associated with both an estimated GFR &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and albuminuria (defined as an ACR ratio &ge;30",
"      <span class=\"nowrap\">",
"       mg/g).",
"      </span>",
"      Among 1156 diabetic patients, PAD was associated with a low estimated GFR but not albuminuria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 955 hypertensive patients, the prevalence of a low ABI was higher among patients with an estimated GFR &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 compared with those with an estimated GFR &ge;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (37 versus 24 percent). Among patients with albuminuria, the prevalence of a low ABI was higher among those with versus those without albuminuria (32 versus 23 percent). The prevalence of a low ABI was 22 percent for those with a preserved estimated GFR and no albuminuria, 27 percent for those with a low estimated GFR and no albuminuria, 29 percent for those with preserved estimated GFR and albuminuria, and 46 percent for those with both albuminuria and a low estimated GFR. While analyses were adjusted for diabetes, results of analyses stratified for diabetes were not reported [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among adults aged 40 and older who participated in the National Health and Nutrition Examination Survey 1999-2004, the prevalence of an ABI &lt;0.90 was 3.6 percent in those with an estimated GFR &ge;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and no albuminuria, 9.7 percent in those with an estimated GFR &ge;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and albuminuria, 14.8 percent in those with an estimated GFR &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and no albuminuria, and 25.3 percent in those with an estimated GFR &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 and albuminuria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The prevalence of diabetes in this cohort was less than 30 percent for all groups examined. While the associations of estimated GFR and albuminuria with a low ABI were present in analyses adjusted for diabetes and other potential confounders, stratified analyses among those with and without diabetes were not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptomatic PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic PAD is more prevalent among individuals with CKD than in the general population. Patients with CKD are also at increased risk for developing clinically significant PAD even after adjustment for other known risk factors, such as older age and diabetes. Furthermore, PAD and CKD appear to have a synergistic effect on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic studies have reported the prevalence of intermittent claudication in the general adult population to be 1 to 5 percent, with a higher prevalence among men and older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/7,8,16,27-32\">",
"     7,8,16,27-32",
"    </a>",
"    ]. In a study from Finland, the prevalence of intermittent claudication among patients with CKD (mean creatinine clearance 30&plusmn;25",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    was 7 percent, compared with zero among those without CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/18\">",
"     18",
"    </a>",
"    ]. The prevalence of PAD in patients with CKD is even higher using additional imaging studies to identify arterial occlusive disease compared with using symptoms (eg, claudication) or ABI criteria alone. In the Finnish study, the prevalence of PAD (abnormal ABI or TBI, or history of abnormal lower extremity arteriogram) was 22 versus 2 percent among patients with CKD and controls, respectively, compared with 15 and 0 percent, respectively, using ABI alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study in which 29 percent of patients were diabetic, PAD was defined as an ABI &le;0.90, or TBI &le;0.60 with medial arterial calcifications in the face of an incompressible ABI &ge;1.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/18\">",
"     18",
"    </a>",
"    ]. Using this definition, the prevalence of PAD was 22, 31, and 15 percent among predialysis, dialysis, and kidney transplant patients, respectively, and the prevalence of medial artery calcifications was 24, 42, and 21 percent, respectively.",
"   </p>",
"   <p>",
"    CKD may also be a risk factor for the development of severe PAD requiring lower extremity revascularization or amputation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Cardiovascular Health Study, individuals with CKD at baseline had a higher incidence of intermittent claudication",
"      <span class=\"nowrap\">",
"       (10.6/1000",
"      </span>",
"      patient-years) compared with individuals with normal kidney function",
"      <span class=\"nowrap\">",
"       (3.5/1000",
"      </span>",
"      patient-years), after a median follow-up of 7.3 years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Heart and",
"      <span class=\"nowrap\">",
"       Estrogen/Progestin",
"      </span>",
"      Replacement Study (HERS), incident lower extremity PAD event rates (revascularization, amputation, or lower extremity sympathectomy) among women with creatinine clearances 30 to 59 and &lt;30",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m2 were 0.9 and 2.7 percent per year, respectively, compared to 0.6 percent per year among women with normal kidney function [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of peripheral artery disease (PAD) are largely similar in patients with and without chronic kidney disease (CKD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, compared with patients with normal kidney function, patients with CKD appear to be more likely to develop critical limb ischemia, to have higher rates of limb loss after revascularization, and to have higher mortality.",
"   </p>",
"   <p>",
"    This was illustrated in a study of 5787 male veterans who received an initial diagnosis of rest pain, ischemic ulceration, or gangrene, among whom 38 percent had an estimated glomerular filtration rate (GFR) &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (but were not on dialysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with CKD had more severe disease at presentation with 77 and 87 percent of those with estimated GFR 30 to 59 and &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, respectively, presenting with gangrene or ischemic ulceration rather than rest pain (versus 70 percent among patients with estimated GFR &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2). In the same study, the presence of CKD was associated with substantially higher one year mortality among patients with critical limb ischemia (50 versus 26 percent among those without CKD).",
"   </p>",
"   <p>",
"    The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (AHA/ACC)",
"    </span>",
"    guidelines identify \"severe renal failure\" as a condition associated with an increased risk of limb loss among patients with critical limb ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a large retrospective study of 9932 patients undergoing initial surgical revascularization reported an increased risk of limb loss during the year after revascularization among patients receiving dialysis, but not among other patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/34\">",
"     34",
"    </a>",
"    ]. It is possible that uncertainty regarding the possible benefits may have led to the lower observed rates of revascularization (versus amputation or no procedure) in a cohort of patients with CKD and incident critical limb ischemia compared with patients without CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of noninvasive tests are available to evaluate for the presence and severity of peripheral artery disease (PAD), including assessment of intermittent claudication, ankle-brachial index (ABI), toe-brachial index (TBI), exercise treadmill test, and others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37128?source=see_link\">",
"     \"Lower extremity peripheral artery disease in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and characterization of PAD using physiologic studies in patients with chronic kidney disease (CKD) may pose some unique challenges. As an example, the ABI may be less reliable in identifying PAD among patients with CKD due to the high prevalence of medial arterial calcification, which can result in falsely elevated lower extremity blood pressure readings due to arterial incompressibility. The previously mentioned Finnish study reported the estimated prevalence of medial arterial calcification of 24 and 3.4 percent among patients with and without kidney dysfunction, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544669#H58544669\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'High ABI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the ABI is elevated (&ge;1.3), the TBI may be more accurate as medial artery calcification is less likely to interfere with toe pressure measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/36\">",
"     36",
"    </a>",
"    ]. An ABI &lt;0.90 and a TBI &lt;0.60 are considered abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58549539#H58549539\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Toe-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although arteriography may be needed to fully evaluate arterial anatomy in patients with critical limb ischemia, the risk of nephrotoxicity related to iodinated radiocontrast administration must be carefully weighed against the benefits of this procedure among patients with CKD. A vascular duplex study may be a helpful preliminary study to identify potential arterial lesions. If revascularization is indicated, imaging and intervention can be planned simultaneously to minimize radiocontrast administration. In addition, efforts to minimize the dose of contrast will help to lower the risk of nephrotoxicity. For patients with distal disease, an antegrade study from the groin selectively imaging the tibial and more distal arteries may provide the necessary information while minimizing contrast exposure. In patients with only modest decrements in estimated glomerular filtration rate (GFR), magnetic resonance angiography (MRA) with gadolinium will often provide high-quality digital images that can be used to plan revascularization procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRA is also accurate and can be performed either without contrast or with a gadolinium-based contrast agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/37\">",
"     37",
"    </a>",
"    ]. Until recently, MRA with gadolinium had been increasingly favored over iodinated contrast angiography as a first-line preoperative arterial imaging technique in patients with CKD because of a lower risk of contrast nephropathy. However, administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis among patients with moderate to advanced renal failure (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    In such patients, gadolinium-based imaging should be avoided if possible. There is no consensus among experts concerning the decision to administer gadolinium among patients with an estimated GFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONSERVATIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have specifically evaluated the impact of medical treatment on peripheral artery disease (PAD) outcomes, such as symptom relief and need for procedures such as revascularization and amputation. In the absence of better data, recommendations for treating PAD are extrapolated from described or presumed benefit of selected interventions in reducing cardiovascular events or modifying markers of cardiovascular risk. Full discussion of accepted and investigational therapies for symptomatic PAD is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk factor modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAD is a marker for more generalized atherosclerosis and is considered a coronary heart disease risk equivalent. In addition, chronic kidney disease (CKD) itself is also a coronary heart disease risk equivalent. As a result, aggressive risk factor reduction is recommended for secondary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of claudication\", section on 'Risk factor modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Statin therapy &ndash; Cholesterol lowering with statins appears to reduce the overall frequency of cardiovascular events among high risk individuals in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/38\">",
"       38",
"      </a>",
"      ]. Thus, statin therapy has been recommended for patients with PAD based on their elevated risk of cardiovascular death, myocardial infarction, and stroke. The Study of Heart Protection (SHARP) trial supports the efficacy of lipid lowering therapy for reducing cardiovascular mortality and cardiovascular events in patients with CKD. This trial randomly assigned 9270 patients with CKD aged 40 years and older to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      10 mg plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      20 mg, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/39\">",
"       39",
"      </a>",
"      ]. The risk of major atherosclerotic events was significantly reduced in the treatment group (risk ratio [RR] 0.83, 95% CI 0.74-0.94) compared with placebo. The need for coronary revascularization was lower in the treatment compared with placebo group. These data suggest that aggressive treatment of hyperlipidemia is effective in lowering the risk of atherosclerotic vascular events in patients with CKD, but specific data for PAD are lacking. The",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      clinical practice guidelines for managing dyslipidemias in CKD, as well as other",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines, can be accessed through the National Kidney Foundation's web site at",
"      <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"       www.kidney.org/professionals/kdoqi/guidelines.cfm",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"       \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antihypertensive agents &ndash; Hypertension is a major risk factor for PAD. However, there are no data evaluating whether antihypertensive therapy alters the progression of PAD in patients with or without kidney disease. Nevertheless, hypertension should be controlled in patients with CKD to reduce morbidity from cardiovascular and cerebrovascular disease and also to delay progression of CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking cessation &ndash; Although the effects of smoking and smoking cessation have not been specifically studied among patients with CKD, smoking is associated with an increased risk of amputation among patients with claudication. Thus, smoking cessation should be strongly encouraged in patients with CKD and PAD given their high risk for PAD events and for other cardiovascular events. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H3#H3\">",
"       \"Medical management of claudication\", section on 'Cigarette smoking'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information regarding the impact of antiplatelet agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), on PAD outcomes such as lower extremity revascularization or amputation in patients with CKD. However, large clinical trials in the general population have demonstrated that antiplatelet agents reduce the risk of cardiovascular events, and may improve patency rates following revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data, antiplatelet therapy is recommended for CKD patients with PAD to reduce the risk of overall cardiovascular events and death, unless contraindications exist (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical management of claudication\", section on 'Pharmacologic therapy'",
"    </a>",
"    ). The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for cardiovascular disease in chronic renal disease, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The 2012 Ninth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy and updated American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines (2011) recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    should be given indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/11,41-43\">",
"     11,41-43",
"    </a>",
"    ]. The guidelines suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75 mg daily) should be considered an alternative treatment, but that aspirin is preferred because the much higher cost of clopidogrel was not justified for the possible small increase in efficacy shown in the CAPRIE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the costs and benefits of aspirin versus clopidogrel have been not specifically assessed in patients with CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cilostazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"     Cilostazol",
"    </a>",
"    , a phosphodiesterase inhibitor that has both antiplatelet and vasodilating properties, is indicated for alleviating intermittent claudication. Cilostazol increases pain-free and maximal walking distance among persons with claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Patients with CKD were not explicitly excluded from these trials but no subgroup analyses were reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is considered first-line therapy for intermittent claudication, although its value in asymptomatic PAD and critical ischemia is unknown. The safety and efficacy of exercise therapy for PAD among patients with CKD has not been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H9#H9\">",
"     \"Medical management of claudication\", section on 'Supervised exercise therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INVASIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for invasive therapy in patients with peripheral artery disease (PAD) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, as any other patient at increased risk for critical limb ischemia, patients with chronic kidney disease (CKD) who develop symptoms consistent with critical limb ischemia should receive immediate evaluation and referral to a specialist competent in treating vascular disease (see American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     [ACC/AHA]",
"    </span>",
"    guideline on critical limb ischemia). The indications for percutaneous and surgical intervention for intermittent claudication and critical limb ischemia recommended by the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines are no different for patients with CKD than for the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38921?source=see_link\">",
"     \"Percutaneous interventional procedures in the patient with lower extremity claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these procedures are generally recommended only when the expected benefits exceed the risk. A prospective cohort study of 456 patients found that five-year survival rates after lower extremity bypass surgery were significantly decreased among those with stage four and five CKD (23 and 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/48\">",
"     48",
"    </a>",
"    ]. Major amputation was also significantly more likely in those with stage five CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies have demonstrated higher mortality and lower limb salvage rates among patients with end-stage renal disease (ESRD) who undergo lower extremity surgical or percutaneous revascularization procedures compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/49-54\">",
"     49-54",
"    </a>",
"    ]. Patients with non-dialysis-dependent CKD are also at increased risk for postoperative mortality after lower extremity revascularization, but limb salvage rates are not substantially different from the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/34,55,56\">",
"     34,55,56",
"    </a>",
"    ]. This was illustrated in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study of 9932 patients undergoing an initial surgical revascularization procedure, a major amputation occurred within one year of lower extremity surgical revascularization among 10, 11, 12, and 29 percent of patients with normal kidney function, moderate CKD (estimated glomerular filtration rate [GFR] &lt;30 to 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2), severe CKD (estimated GFR &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2), and dialysis patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 56 patients with serum creatinine concentration &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      who underwent 70 autogenous vein bypass procedures, the five-year cumulative limb salvage rate was 80 percent, with a primary graft patency of 74 percent and a secondary patency of 77 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/55\">",
"       55",
"      </a>",
"      ]. This was similar to expected outcomes among patients with normal kidney function at that institution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, when compared with amputation or no intervention, revascularization appears to be associated with improved survival among patients with CKD. As an example, in a retrospective analysis of 6000 male veterans with critical limb ischemia, revascularization was associated with the lowest mortality at each level of kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/21\">",
"     21",
"    </a>",
"    ]. In analyses adjusted for level of kidney function and comorbidity, a higher odds ratio of death was noted for amputation (OR 1.7, 95% CI 1.4-1.0) and conservative management (OR 1.6, 95% CI 1.3-1.9) compared with revascularization. These results must be interpreted with some caution as they may reflect selection bias rather than a true benefit to revascularization in patients with CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amputation is considered a last resort when revascularization has failed or is not an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with CKD have an increased risk of death after amputation and revascularization compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/35,56\">",
"     35,56",
"    </a>",
"    ]. This was illustrated in a study of 17,000 patients undergoing their first amputation, in which postoperative (30-day) mortality was 9, 15, and 16 percent in patients with moderate CKD, severe CKD, and on dialysis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/35\">",
"     35",
"    </a>",
"    ]. By comparison, postoperative mortality was 6 percent in those with estimated GFR &ge;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. These postoperative mortality rates are considerably higher than for lower extremity revascularization in patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/56\">",
"     56",
"    </a>",
"    ], most likely reflecting the greater severity of PAD (and perhaps other comorbidities) among patients undergoing an amputation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral artery disease (PAD) appears to be more prevalent among patients with chronic kidney disease (CKD) than in the general population. The clinical manifestations of PAD are largely similar in patients with and without CKD, with limited data suggesting that patients with CKD may have more severe disease at presentation and are at increased risk for limb loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no data to support screening for PAD in patients with CKD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20905/abstract/22\">",
"       22",
"      </a>",
"      ]. For the diagnosis of PAD in patients with CKD, we recommend using the ankle-brachial index (ABI), and when the ABI is elevated, using the toe-brachial index (TBI). An ABI &lt;0.90 and a TBI &lt;0.60 are considered abnormal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24200?source=see_link\">",
"       \"Screening for lower extremity peripheral artery disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"       \"Noninvasive diagnosis of arterial disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For preoperative evaluation, there are issues surrounding the use of magnetic resonance angiography (MRA) in patients with CKD given that the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis among patients with moderate to advanced renal failure (dialysis-dependent or estimated GFR less than 30",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      This is discussed above and separately (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      ). Issues concerning the use of iodinated contrast arteriography are also presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"       \"Prevention of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although smoking cessation, statins, and antihypertensive therapy have not been shown to reduce PAD events specifically in patients with CKD, we recommend that these be implemented for secondary prevention of cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H11#H11\">",
"       \"Chronic kidney disease and coronary heart disease\", section on 'Reduction of CHD risk in patients with CKD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"       \"Medical management of claudication\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend antiplatelet therapy for patients with PAD to reduce the risk of overall cardiovascular events and death unless contraindications exist (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We agree with the approach in the 2012 Ninth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy and the 2011 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association",
"      <span class=\"nowrap\">",
"       (ACC/AHA)",
"      </span>",
"      updated guidelines on PAD:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75 mg daily) should be given to all patients for cardiovascular protection, with aspirin being preferred because of the much greater cost of clopidogrel with only a possible small increase in efficacy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H12#H12\">",
"       \"Medical management of claudication\", section on 'Antiplatelet agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      for symptom management of patients with claudication, although its effectiveness in the CKD population has not been studied (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H451547835#H451547835\">",
"       \"Medical management of claudication\", section on 'Cilostazol'",
"      </a>",
"      ). Among patients with symptomatic lower extremity PAD, we also recommend a regimen of intermittent walking be instituted, if the patient is capable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H9#H9\">",
"       \"Medical management of claudication\", section on 'Supervised exercise therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for treatment with angioplasty or bypass for claudication and critical limb ischemia are no different than for the general population, but decision-making in patients with CKD must be individualized to reflect their greater risk of perioperative mortality after both of these procedures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"       \"Indications for surgery in the patient with lower extremity claudication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"       \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"       \"Treatment of chronic lower extremity critical limb ischemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author would like to thank Drs. William R. Hiatt and Ted. R Kohler for valuable input on this review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/1\">",
"      Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/2\">",
"      Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/3\">",
"      Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/4\">",
"      Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/5\">",
"      Shlipak MG, Simon JA, Grady D, et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001; 38:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/6\">",
"      Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/7\">",
"      Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/8\">",
"      Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/9\">",
"      Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/10\">",
"      Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/11\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/12\">",
"      O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004; 109:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/13\">",
"      O'Hare AM, Vittinghoff E, Hsia J, Shlipak MG. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 2004; 15:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/14\">",
"      Wattanakit K, Folsom AR, Selvin E, et al. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2007; 18:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/15\">",
"      Carter SA. Indirect systolic pressures and pulse waves in arterial occlusive diseases of the lower extremities. Circulation 1968; 37:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/16\">",
"      Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997; 131:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/17\">",
"      Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999; 19:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/18\">",
"      Leskinen Y, Salenius JP, Lehtim&auml;ki T, et al. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002; 40:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/19\">",
"      Shlipak MG, Fried LF, Crump C, et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 2002; 62:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/20\">",
"      Wattanakit K, Folsom AR, Criqui MH, et al. Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2008; 201:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/21\">",
"      O'Hare AM, Bertenthal D, Sidawy AN, et al. Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. Clin J Am Soc Nephrol 2006; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/22\">",
"      DeLoach SS, Mohler ER 3rd. Peripheral arterial disease: a guide for nephrologists. Clin J Am Soc Nephrol 2007; 2:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/23\">",
"      Wu CK, Yang CY, Tsai CT, et al. Association of low glomerular filtration rate and albuminuria with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis 2010; 209:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/24\">",
"      Mostaza JM, Suarez C, Manzano L, et al. Relationship between ankle-brachial index and chronic kidney disease in hypertensive patients with no known cardiovascular disease. J Am Soc Nephrol 2006; 17:S201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/25\">",
"      Baber U, Mann D, Shimbo D, et al. Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol 2009; 104:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/26\">",
"      Liew YP, Bartholomew JR, Demirjian S, et al. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. Clin J Am Soc Nephrol 2008; 3:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/27\">",
"      Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/28\">",
"      Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med 2003; 163:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/29\">",
"      Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/30\">",
"      Newman AB, Naydeck BL, Sutton-Tyrrell K, et al. The role of comorbidity in the assessment of intermittent claudication in older adults. J Clin Epidemiol 2001; 54:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/31\">",
"      Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation 1970; 41:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/32\">",
"      Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/33\">",
"      O'Hare AM, Bertenthal D, Shlipak MG, et al. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 2005; 16:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/34\">",
"      O'Hare AM, Sidawy AN, Feinglass J, et al. Influence of renal insufficiency on limb loss and mortality after initial lower extremity surgical revascularization. J Vasc Surg 2004; 39:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/35\">",
"      O'Hare AM, Feinglass J, Reiber GE, et al. Postoperative mortality after nontraumatic lower extremity amputation in patients with renal insufficiency. J Am Soc Nephrol 2004; 15:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/36\">",
"      Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/37\">",
"      Koelemay MJ, Lijmer JG, Stoker J, et al. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. JAMA 2001; 285:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/38\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/39\">",
"      Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/40\">",
"      Feringa HH, Karagiannis SE, Chonchol M, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007; 18:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/41\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/42\">",
"      Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. Catheter Cardiovasc Interv 2012; 79:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/43\">",
"      Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:609S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/44\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/45\">",
"      Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/46\">",
"      Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/47\">",
"      Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/48\">",
"      Owens CD, Ho KJ, Kim S, et al. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg 2007; 45:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/49\">",
"      Harrington EB, Harrington ME, Schanzer H, Haimov M. End-stage renal disease--is infrainguinal limb revascularization justified? J Vasc Surg 1990; 12:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/50\">",
"      Johnson BL, Glickman MH, Bandyk DF, Esses GE. Failure of foot salvage in patients with end-stage renal disease after surgical revascularization. J Vasc Surg 1995; 22:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/51\">",
"      Korn P, Hoenig SJ, Skillman JJ, Kent KC. Is lower extremity revascularization worthwhile in patients with end-stage renal disease? Surgery 2000; 128:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/52\">",
"      Lantis JC 2nd, Conte MS, Belkin M, et al. Infrainguinal bypass grafting in patients with end-stage renal disease: improving outcomes? J Vasc Surg 2001; 33:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/53\">",
"      Lumsden AB, Besman A, Jaffe M, et al. Infrainguinal revascularization in end-stage renal disease. Ann Vasc Surg 1994; 8:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/54\">",
"      Wassermann RJ, Saroyan RM, Rice JC, Kerstein MD. Infrainguinal revascularization for limb salvage in patients with end-stage renal disease. South Med J 1991; 84:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/55\">",
"      Whittemore AD, Donaldson MC, Mannick JA. Infrainguinal reconstruction for patients with chronic renal insufficiency. J Vasc Surg 1993; 17:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20905/abstract/56\">",
"      O'Hare AM, Feinglass J, Sidawy AN, et al. Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: data from the Department of Veterans Affairs' National Surgical Quality Improvement Program. J Am Soc Nephrol 2003; 14:1287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7223 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20905=[""].join("\n");
var outline_f20_26_20905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354921524\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptomatic PAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONSERVATIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk factor modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cilostazol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INVASIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Amputation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=related_link\">",
"      Indications for surgery in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37128?source=related_link\">",
"      Lower extremity peripheral artery disease in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38921?source=related_link\">",
"      Percutaneous interventional procedures in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24200?source=related_link\">",
"      Screening for lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_26_20906="Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance";
var content_f20_26_20906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Thomas C Gerber, MD, PhD, FACC, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/26/20906/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/26/20906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress testing is the traditional noninvasive approach to detecting obstructive coronary artery disease. Stress testing provides physiologic evidence of clinically significant coronary artery stenoses by demonstrating the effects of diminished coronary flow reserve on symptoms, characteristic changes on the electrocardiogram, myocardial perfusion defects on scintigraphy, or regional wall motion abnormalities on echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nondiagnostic findings or strong clinical suspicion conflicting with the findings on stress testing may suggest the need for direct (anatomic) assessment of the coronary artery lumen with invasive coronary arteriography. However, catheter-based angiography is expensive and is associated with a small risk of serious complications that are directly related to its invasive nature and to the use of iodinated contrast media. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    .) In addition, 50 percent or more of patients referred for an elective coronary angiogram are found to not have significant coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improving safety and cost effectiveness provided most of the rationale for the development of noninvasive methods of coronary angiography. Noninvasive visualization of coronary arteries is rendered difficult by their small caliber, tortuous course, and almost constant motion. Thus, potential imaging modalities must possess high temporal and spatial resolution.",
"   </p>",
"   <p>",
"    Noninvasive coronary arteriography was first described for cardiovascular magnetic resonance imaging (CMRI) in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/2\">",
"     2",
"    </a>",
"    ] and for computed tomography (CT) in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/3\">",
"     3",
"    </a>",
"    ]. The clinical use of these techniques, particularly CT, is becoming widely available and increasingly popular.",
"   </p>",
"   <p>",
"    The technical issues associated with and results of studies evaluating the use of CT and CMRI for noninvasive coronary angiography will be reviewed here. Potential indications will also be discussed. The use of CT to detect coronary artery calcification is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Per patient versus per segment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies examining the diagnostic accuracy by noninvasive coronary angiography usually report their findings in terms of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Per patient",
"     </li>",
"     <li>",
"      Per coronary segment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The per patient results are most meaningful and will be emphasized in the following discussion because they reflect how many patients are correctly identified as having at least one \"significant\" coronary stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidental findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;When coronary arteries are imaged by CT or CMRI, noncardiac structures are also visualized and require interpretation, as noted in the American College of Radiology guidelines for interpretation of cardiac CT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/4\">",
"     4",
"    </a>",
"    ] and CMRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary studies suggest that some of these incidental noncardiac findings are clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Examples include pulmonary embolism, large pleural effusions, sarcoidosis, pulmonary nodules, and malignancy. Potential risks and benefits of incidental findings have been better studied with total body imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16952?source=see_link&amp;anchor=H9#H9\">",
"     \"Full body CT scan for screening\", section on 'Risks of screening with FBCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiac and coronary CT imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary CT angiography (CCTA) has a relatively low technical burden for both the operator and patient. The scanning time to acquire a three-dimensional dataset of the entire heart can take as little as 5 seconds.",
"   </p>",
"   <p>",
"    Most CCTA procedures are currently performed with multidetector row or multislice (MDCT or MSCT) scanners.",
"   </p>",
"   <p>",
"    The relative test performance of CCTA and cardiovascular magnetic resonance angiography are discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Comparison of CCTA and CMRI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     MDCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDCT scanners use mechanically rotating gantries. Scanners from different manufacturers vary slightly in their technical specifications but all have two features in common: a temporal resolution high enough to allow imaging of the beating heart without motion artifact if the heart rate is regular and slow (usually less than 60 to 70",
"    <span class=\"nowrap\">",
"     beats/min);",
"    </span>",
"    and acquisition of more than one image slice per gantry rotation.",
"   </p>",
"   <p>",
"    The temporal resolution of an MDCT scanner is defined by its gantry rotation time. MDCT scanners used for CCTA should have a gantry rotation time of less than 420 msec (corresponding to a temporal resolution of less than 210 msec), and should allow an x-ray beam collimation of less than 1 mm.",
"   </p>",
"   <p>",
"    MDCT technology is evolving continuously and rapidly. Most MDCT scanners now in use acquire at least 64 slices (also known as rows) simultaneously with a collimation of 0.6 mm with a gantry rotation time of 333 msec (corresponding to a temporal resolution of approximately 167 msec) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. The newest single-source MDCT scanners can acquire 256 or 312 slices with each gantry rotation.",
"   </p>",
"   <p>",
"    A dual",
"    <span class=\"nowrap\">",
"     source/dual",
"    </span>",
"    energy MDCT scanner is also available, which effectively reduces temporal resolution by 50 percent to 83 msec, thereby facilitating imaging without the need for beta blockers in many patients.",
"   </p>",
"   <p>",
"    To facilitate scanning and optimize image quality, most patients undergoing CCTA with most current MDCT scanners receive oral or intravenous beta blockers or both to slow the heart rate to less than 60 to 70",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is sometimes given immediately before the scan to achieve vasodilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following patient-related factors can interfere with the diagnostic quality of CCTA images [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/10,11,13-16\">",
"     10,11,13-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart rate greater than 60 or 70",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"     </li>",
"     <li>",
"      Irregular heart rhythm (atrial fibrillation or frequent atrial or ventricular extrasystoles)",
"     </li>",
"     <li>",
"      Inability to sustain a breath hold for at least five seconds",
"     </li>",
"     <li>",
"      Severe coronary calcification or the presence of coronary artery stents, since image reconstruction artifacts related to radiodense material such as calcium or metal can obscure the coronary artery lumen [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H14\">",
"       'Test methodology'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H36\">",
"       'Coronary artery stents'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Segments with a diameter &lt;1.5 mm can usually not be assessed for stenosis. Such small vessel caliber is typical of distal coronary artery segments and some side branches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These technical and image quality problems may be overcome with improvements in future generations of CT scanners (eg, gantry rotation speed, number and thickness of slices acquired simultaneously, dual energy scanning, or image reconstruction algorithms).",
"   </p>",
"   <p>",
"    Injection of iodinated contrast medium is required for MDCT coronary angiography. In most cases, 60 to 120 mL is injected intravenously at a rate of 2 to 5",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Thus, CCTA is contraindicated in patients with a history of allergy to iodinated contrast medium and relatively contraindicated in patients at high risk for contrast nephropathy (eg, patients with diabetes and a serum creatinine concentration above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [177",
"    <span class=\"nowrap\">",
"     &micro;mol/L]).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation dose from CCTA, potential risks and options for dose reduction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=see_link\">",
"     \"Radiation dose and risk of malignancy from cardiovascular imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance imaging (CMRI) has technical requirements for imaging of the coronary arteries similar to those of CT. Advantages of coronary MR imaging (CMRI) over CCTA include the absence of exposure to ionizing radiation and iodinated contrast media and the lack of necessity for heart rate control with beta blockers. These features facilitate sequential studies and permit imaging in younger patients and those with renal dysfunction.",
"   </p>",
"   <p>",
"    In addition, coronary artery calcification, which lowers specificity with CCTA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/10,11,17\">",
"     10,11,17",
"    </a>",
"    ], is not prominent on CMRI images because of its low proton content. As a result, detection of coronary lesions in heavily calcified coronary segments by CMRI can be more reliable than by CCTA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several relative disadvantages and limitations to the use of CMRI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The procedure requires considerable skill on the part of the operator, the approaches are currently vendor specific, and the entire acquisition can be time-consuming (30 minutes or more).",
"     </li>",
"     <li>",
"      CMRI is relatively contraindicated in the presence of certain implanted foreign bodies or medical devices that consist mostly or entirely of metal or contain electrical circuitry (eg, pacemakers, implantable cardioverter-defibrillators). An important exception is the presence of a coronary artery stent. Irrespective of stent type and the time since implantation, stents are not a contraindication to MRI. However, the stent may interfere with local image quality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link&amp;anchor=H25#H25\">",
"       \"General principles of the use of intracoronary stents\", section on 'Safety of MRI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Irregular heart rhythms, inability to comply with breath-holding instructions (for breath-holding approaches), and an irregular breathing pattern (free breathing approaches) will result in poor image quality.",
"     </li>",
"     <li>",
"      There is variability for both imaging and respiratory motion suppression among the CMRI sequences from different vendors. Although two-dimensional image acquisitions were used initially [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/2\">",
"       2",
"      </a>",
"      ], targeted three-dimensional or whole heart CMRI methods analogous to CCTA now predominate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared to CCTA, the spatial resolution of CMRI is lower, but the temporal resolution is more flexible: the length of the data acquisition window is based upon the patient's heart rate, rather than being fixed and determined by gantry rotation speed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY STENOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Coronary CT angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have examined the diagnostic accuracy of CCTA for detecting coronary artery stenoses. Most studies of CCTA published to date are single center studies that describe the findings of experienced observers in relatively small numbers of patients who were referred for x-ray coronary angiography and had a relatively high prevalence of disease. The diagnostic accuracy that can be expected among patient populations with a lower prevalence of disease or from less experienced observers is not known. Training standards for practitioners and interpreters of CTCA have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/20\">",
"     20",
"    </a>",
"    ] and certification procedures have been introduced (information at",
"    <a class=\"external\" href=\"file://cbcct.org\">",
"     cbcct.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Test methodology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most CCTA studies have used a visual estimate of &gt;50 percent diameter stenosis on invasive, selective coronary angiography as the definition of a \"significant\" stenosis. However, stenoses of less than 70 percent are typically not flow-limiting, are rarely the cause of ischemia or angina, and usually do not require revascularization. Thus, the sensitivities reported in the literature may not reflect the ability of CCTA to identify those patients with chest pain who will need catheter-based or surgical revascularization. This problem is reflected in the discrepant diagnostic accuracies of stress testing (functional evaluation) and anatomic imaging with CCTA in studies that compared these two approaches. The degree of luminal narrowing on CCTA has been determined only by visual estimate in most studies to date.",
"   </p>",
"   <p>",
"    Many CCTA studies prior to 2000 were performed on EBCT scanners that are no longer in use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The vast majority of CCTA examinations are now performed with MDCT scanners [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/23\">",
"     23",
"    </a>",
"    ]. Among the studies of CCTA with MDCT, the overall image quality and diagnostic accuracy have improved with successive scanner generations (due to increase in number of detector rows, decrease in slice thickness, and higher gantry speed) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Impact of coronary calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the ACCURACY trial and other studies, specificity is reduced in the presence of coronary artery calcium (eg, 86 versus 53 percent for detection of &ge;50 percent stenosis with calcium scores &le;400 versus &gt;400 Agatston units) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/10,11,26\">",
"     10,11,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Multicenter studies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Single center studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings were noted in a review of single center studies comparing 64-slice MDCT and invasive coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 23 studies including results in 2045 patients, the per patient pooled sensitivity for significant (&ge;50 percent) stenosis was 98 percent (range 88 to 100 percent) and the pooled specificity was 88 percent (range 59 to 100 percent).",
"     </li>",
"     <li>",
"      In 21 studies, the per segment pooled sensitivity for significant (&ge;50 percent) stenosis was 90 percent (range 73 to 100 percent) and the pooled specificity was 96 percent (range 90 to 99 percent). Approximately 8 percent of segments were unevaluable and were excluded from the calculations for sensitivity and specificity.",
"     </li>",
"     <li>",
"      Data from four studies for detection of high-grade (&ge;70 percent) stenosis yielded a pooled sensitivity of 91 percent and a pooled specificity of 88 percent. Segment-based analysis yielded a pooled sensitivity of 82 percent and a pooled specificity of 97 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Multicenter studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three multicenter studies evaluated the diagnostic accuracy of 64-slice MDCT CCTA for detection of significant (at least 50 percent diameter stenosis) coronary artery disease on quantitative invasive x-ray coronary angiography.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the multicenter, single vendor, US based ACCURACY trial, 230 (94 percent) of 245 enrolled subjects completed the study protocol and all scans were evaluated visually [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/26\">",
"       26",
"      </a>",
"      ]. Patient-based sensitivity and specificity of CCTA were 95 percent and 83 percent, respectively. Specificity fell to 53 percent for patients with calcium scores &gt;400 Agatston units.",
"     </li>",
"     <li>",
"      In the multicenter, single vendor international CORE 64 study, 291 (72 percent) of 405 enrolled patients were eligible for analysis since they had calcium scores of &le;600 and completed the protocol [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/28\">",
"       28",
"      </a>",
"      ]. Patient-based sensitivity and specificity of CCTA were 85 percent and 90 percent, respectively.",
"     </li>",
"     <li>",
"      In a multicenter, multivendor study performed in the Netherlands, 360 (97 percent) of 371 enrolled patients completed the protocol and all CCTA scans were visually evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/29\">",
"       29",
"      </a>",
"      ]. Patient-based sensitivity and specificity of CCTA were 99 percent and 64 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive and negative predictive values for CCTA detection of significant stenoses as compared to invasive x-ray coronary angiography will vary with the prevalence of disease in the population studied. In the above cited review, the average prevalence of significant (&ge;50 percent diameter stenosis) coronary artery disease detected by invasive coronary angiography was 61 percent; prevalences were 25, 56 and 68 percent in the multicenter studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the review, positive predictive values ranged from 91 to 93 percent for patient-based evaluations, left main coronary artery, and coronary artery bypass grafts and from 69 to 84 percent for other coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/27\">",
"     27",
"    </a>",
"    ]. In the multicenter studies, the positive predictive values for patient-based analyses were 64, 91 and 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Negative predictive values for CCTA have generally been high (eg, 95 to 100 percent in the review and two of the multicenter studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/26,27,29\">",
"     26,27,29",
"    </a>",
"    ] but were lower (eg, 83 percent for patient-based detection of significant disease) in one of the multicenter studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/28\">",
"     28",
"    </a>",
"    ]. The generally high observed negative predictive values have prompted interest in use of CCTA in certain clinical scenarios where invasive coronary angiography is currently used to \"rule out\" coronary artery stenoses. However, this approach has not been rigorously studied. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Other uses'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H37\">",
"     'Guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Combined testing with SPECT rMPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the improvements in specificity and percentage of evaluable segments mentioned above, limitations of CCTA remain, such as the inability to address the physiologic impact of any lesions and a persistently suboptimal specificity. A first report of a combined CT (16",
"    <span class=\"nowrap\">",
"     slice)/single-photon",
"    </span>",
"    emission computed tomography (SPECT) scanner included 56 patients with known or suspected CAD who underwent pharmacologic or exercise stress [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/30\">",
"     30",
"    </a>",
"    ]. All patients underwent invasive coronary angiography within four weeks of the procedure. Twelve (21 percent) patients and 54 (24 percent) of 224 coronary segments were excluded from analysis due to technical limitations.",
"   </p>",
"   <p>",
"    Compared to the ability of CCTA to detect stenotic lesions in coronary arteries using x-ray coronary angiography as the gold standard, the use of",
"    <span class=\"nowrap\">",
"     CCTA/SPECT",
"    </span>",
"    to detect hemodynamically significant lesions using x-ray coronary angiography and rMPI-SPECT as the gold standard had the following major benefits in the 44 evaluable patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The sensitivity increased from 84 to 96 percent.",
"     </li>",
"     <li>",
"      The specificity increased from 74 to 95 percent.",
"     </li>",
"     <li>",
"      With respect to predictive values, which will vary between patient populations with differing prevalence of disease, the positive predictive value increased from 61 to 77 percent and the negative predictive value increased from 90 to 99 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further studies are anticipated, particularly those using higher resolution CT machines. But combined SPECT and CCTA exposes the patient to even greater doses of potentially harmful ionizing radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Coronary MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are not sufficient to support clinical CMRI for the routine identification of coronary artery stenoses in patients with chest pain or for the screening of patients with multiple risk factors for coronary artery disease. However, the available literature supports a clinical role for CMRI in the assessment of congenital coronary anomalies and coronary artery aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Coronary artery anomalies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The test performance of CMRI for identifying coronary artery stenoses using a free breathing targeted 3D k-space gradient echo sequence with a 1.5 Tesla system was illustrated in a multicenter study of 109 patients in whom 636 (84 percent) of 759 proximal and middle coronary segments could be imaged with diagnostic image quality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/32\">",
"     32",
"    </a>",
"    ]. Using quantitative invasive, selective coronary angiography as the reference standard and interpreting the CMRI by visual estimation, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ge;50 percent stenoses in any coronary artery of any patient were predicted with a sensitivity and specificity of 93 and 42 percent, respectively.",
"     </li>",
"     <li>",
"      Per segment sensitivity and specificity were 83 and 73 percent, respectively.",
"     </li>",
"     <li>",
"      Per patient sensitivity and specificity for the diagnosis of left main or multivessel coronary artery disease were 100 and 85 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent single center reports using improved technical approaches demonstrated improved sensitivities of 80 to 90 percent and specificities of greater than 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Similar findings have been noted in limited data using 3 Tesla CMRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter study from Japan was performed in 138 patients using a whole-heart MR coronary imaging technique. Acquisition of images was successfully completed in 92 percent of patients. The sensitivity of CMRI was 88 percent and the specificity was 72 percent for detection coronary artery stenosis &ge;50 percent by x-ray angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A limitation of CMRI is that test performance with contemporary technology (1.5 Tesla, three-dimensional navigator echo) can vary with operator experience. The potential magnitude of this effect was illustrated in a study in which a 1.5 Tesla MR scanner was used in 21 patients; all images from two patients and four coronary segments from the remaining 19 patients were excluded from analysis because of poor image quality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/37\">",
"     37",
"    </a>",
"    ]. Two observers interpreted the remaining 186 proximal, middle or distal coronary segments. For the prediction of &ge;50 percent stenoses by the two observers, sensitivity was 44 and 56 percent and the specificity was 95 and 84 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Comparison of CCTA and CMRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 51 studies compared the diagnostic performance of multislice CCTA and CMRI for the detection of &ge;50 percent diameter stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/38\">",
"     38",
"    </a>",
"    ]. Multislice CCTA had significantly higher sensitivity (85 versus 72 percent with CMRI) and specificity (95 versus 87 percent).",
"   </p>",
"   <p>",
"    Two studies, published after the meta-analysis, performed head-to-head comparisons of 16-slice CCTA and CMRI in patients who underwent both noninvasive tests before invasive, selective coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/16,39\">",
"     16,39",
"    </a>",
"    ]. The following findings were noted in a study of 52 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On a per patient basis, CCTA and CMRI had similar sensitivity (92 versus 88 percent) and specificity (67 versus 50 percent) for the detection, by visual estimate, of at least one &ge;50 percent coronary artery stenosis.",
"     </li>",
"     <li>",
"      Test performance was also similar on a per segment basis (sensitivity 77 versus 75 percent, specificity 79 versus 82 percent) and a per vessel basis (sensitivity 73 versus 80 percent, specificity 79 versus 86 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second direct comparison of CCTA and CMRI was performed in 108 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/39\">",
"     39",
"    </a>",
"    ]. The per patient sensitivity was significantly better with CCTA (92 versus 74 percent) and the specificities were similar, although a combination of free-breathing and lower resolution breathhold coronary MRI methods were used that had previously been shown to have inferior results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/40\">",
"     40",
"    </a>",
"    ]. These findings were similar to those of the prior meta-analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY BYPASS GRAFT STENOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Coronary CT angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery bypass grafts (CABG) can usually be imaged with good quality because of their relatively large caliber and the lack of motion of at least their proximal portions. In comparison, the distal anastomosis can be difficult to assess with confidence because it moves with the coronary artery and its dimensions approximate those of a middle or distal coronary artery segment (ie, &le;2 mm). These problems have diminished with each successive generation of CT scanner.",
"   </p>",
"   <p>",
"    The diagnostic accuracy of 64-slice MDCT in symptomatic patients after CABG has been evaluated in studies in which invasive coronary arteriography has been used as the gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In a report of 138 consecutive patients with a total of 418 arterial and venous bypass grafts, 64-slice MDCT had both a sensitivity and specificity of 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/42\">",
"     42",
"    </a>",
"    ]. The ability to assess both venous and arterial conduits was 98 percent, but this number fell in patients with arrhythmias or with heart rates greater than 65",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"   </p>",
"   <p>",
"    In patients with prior CABG in whom CCTA is being considered, evaluation of the native circulation is equally important to that of the bypass vessels, since myocardial ischemia may result from new lesions in previously unbypassed vessels or in bypassed vessels distal to the anastomosis. In the first publication comparing 64-slice CT to quantitative coronary angiography for the evaluation of both CABG and native circulation, the following findings were noted in 50 patients with suspected symptomatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All CABG grafts were evaluable and correctly classified as occluded or patent. The sensitivity and specificity for stenosis detection in CABG was 100 and 94 percent respectively",
"     </li>",
"     <li>",
"      In 17 patients, at least one segment of the native coronary circulation was not evaluable and for the purpose of analysis, these patients were labeled as positive for the presence of stenosis since such patients would be referred for invasive angiography. The sensitivity and specificity for stenosis detection in native coronary arteries and distal runoff vessels was 97 and 86 percent respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the high diagnostic accuracy of 64-slice CT angiography, the authors concluded that its clinical utility in patients with CABG remains uncertain. In patients perceived to have a high pretest probability, many will be referred for invasive angiography regardless of the findings on CCTA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Coronary MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the limitations of CMRI in native coronary arteries cited above, reverse saphenous vein and internal mammary artery grafts are relatively easy to image by CMRI due to their relatively stationary position during the cardiac and respiratory cycle and their larger lumen. Furthermore, their predictable and less convoluted course has allowed imaging of bypass grafts even with conventional CMRI techniques. Limitations of bypass graft assessment with CMRI include local signal image artifacts caused by metallic vascular clips and sternal wires.",
"   </p>",
"   <p>",
"    Older studies used conventional spin-echo (black blood) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], gradient echo (bright blood) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], and contrast enhanced CMRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/47\">",
"     47",
"    </a>",
"    ] to determine bypass graft patency. Sensitivity and specificity for detecting graft patency ranged from 86 to 98 percent and 78 to 96 percent, respectively.",
"   </p>",
"   <p>",
"    A later 2003 report using improved techniques evaluated 173 consecutive patients who were referred for invasive coronary angiography because of recurrent chest pain after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/48\">",
"     48",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flow scans could be obtained in 80 percent of grafts",
"     </li>",
"     <li>",
"      For single vein grafts with &gt;50 percent stenosis, the sensitivity and specificity were 94 and 63 percent, respectively",
"     </li>",
"     <li>",
"      For single vein grafts with &gt;70 percent stenosis, the sensitivity and specificity were 96 and 92 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery anomalies may be congenital or acquired (eg, Kawasaki disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Congenital anomalies of origin and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of sudden cardiac arrest is increased in patients with congenital coronary anomalies when the proximal segment of an anomalous coronary artery courses between the aorta and the pulmonary artery. In this setting, the anomalous vessel may become compressed, leading to myocardial ischemia and possibly fatal arrhythmias. This is most likely to occur during periods of high cardiac output, as in young athletes and military recruits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link\">",
"     \"Congenital and pediatric coronary artery abnormalities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether an anomalous coronary artery follows such a malignant \"interarterial course\" or whether it courses in a benign fashion in front of the pulmonary artery or behind the aorta can be determined by CCTA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] and by CMRI with very high accuracy and often much greater ease than by invasive, selective coronary angiography.",
"   </p>",
"   <p>",
"    The ability of CMRI to reliably identify the proximal course of the major coronary arteries and the desire to minimize radiation exposure makes CMRI an ideal procedure to image young adults with suspected coronary anomalies. The data supporting the efficacy of these approaches is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital and pediatric coronary artery abnormalities\", section on 'Variations of coronary artery origin from the aorta'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Coronary artery aneurysms/Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of acquired coronary artery aneurysms are due to Kawasaki disease, a generalized vasculitis occurring in infants and young children. Coronary artery aneurysms occur in 20 to 25 percent of patients with Kawasaki disease who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . In two comparative studies with a total of 19 children, adolescents, and young adults with coronary aneurysms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ectasia, CMRI was as accurate as conventional invasive coronary angiography in identifying and defining (aneurysm diameter and length) the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMRI has the advantage of not requiring ionizing radiation which, if needed, permits serial studies. A limitation of this technique is that the operator must make many repetitive attempts at compound angle tomography to delineate each coronary artery. Thus, patients younger than eight years of age may be difficult to examine by CMRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER USES",
"    </span>",
"   </p>",
"   <p>",
"    The use of CCTA is being examined for situations which make use of its generally high negative predictive value and situations in which the accuracy of stress testing is reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Left bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of complete left bundle branch block (LBBB) in an electrocardiogram suggests underlying heart disease, particularly coronary artery disease, and is associated with an increased risk of cardiac mortality. Pharmacologic radionuclide myocardial perfusion imaging or echocardiography has been used to evaluate patients with LBBB, but the sensitivity and specificity of these tests is suboptimal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\", section on 'Left bundle branch block'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic accuracy of 64 slice MDCT for the detection of coronary stenoses using coronary arteriography as the gold standard was evaluated in 66 patients without a history of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/53\">",
"     53",
"    </a>",
"    ]. The sensitivity and specificity on a per patient basis was 97 and 95 percent respectively and the sensitivity on a per lesion basis was 72 percent. These values are similar to those in patients without LBBB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Before non-coronary cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of 64-slice CCTA to exclude the need for concomitant coronary artery bypass surgery in patients undergoing cardiac valve surgery has been evaluated in a few single center studies. These have demonstrated high sensitivity for detecting significant coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 70 patients referred for cardiac valve surgery (31 with aortic stenosis, 24 with mitral regurgitation, and nine with aortic regurgitation) the prevalence of significant coronary artery disease, defined as the presence of at least one lesion with stenosis diameter of &ge;50 percent, was 26 percent. The sensitivity of CCTA was 100 percent and specificity was 92 percent.",
"     </li>",
"     <li>",
"      In a study of 55 relatively young patients referred for valve replacement for aortic stenosis, the prevalence of significant coronary artery disease was 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/55\">",
"       55",
"      </a>",
"      ]. The sensitivity of CCTA was 100 percent and its specificity was 80 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dilated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive coronary artery disease can be the cause of left ventricular dysfunction, and coronary angiography is frequently performed in patient with newly recognized dysfunction to distinguish between ischemic cardiomyopathy and idiopathic, dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential role of MDCT in identifying ischemic heart failure has been evaluated in single center studies using 64-slice MDCT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. MDCT correctly identified 46 of 50 (92 percent) patients without and 42 of 43 (98 percent) of patients with coronary artery disease, 60 of 62 (97 percent) of patients without and 28 of 31 (90 percent) with ischemic cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cardiac allograft vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplant recipients undergo frequent invasive, selective coronary angiography to address the possibility of transplant vasculopathy. The potential efficacy of 16-slice MDCT for detection of cardiac allograft vasculopathy has been evaluated in two reports of 53 and 54 heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The images of three of 107 patients could not be interpreted because of technical problems; in the remaining patients 96 and 95 percent were imaged in diagnostic quality. The sensitivity and specificity for the detection of &ge;50 percent coronary artery stenoses were 83 to 86 and 95 to 99 percent, respectively on a per segment basis. In the second study, the sensitivity and specificity on a per patient basis was 94 and 79 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of 64-slice MDCT for detection of cardiac allograft vasculopathy has been evaluated in two reports, each with 20 transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Overall agreement between MDCT and invasive angiography was good, and in the study that included intravascular ultrasound, MDCT had a sensitivity of 70 percent and specificity of 92 percent for detection of vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Plaque imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of CCTA with MDCT to detect subclinical noncalcified plaque that is no more than moderately obstructive and the implications of such plaques for cardiovascular risk are the subject of intense research [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. At present, the significance of noncalcified plaque seen on CCTA is not well understood. As a result, clinical management decisions should not be based upon the presence or absence of such lesions.",
"   </p>",
"   <p>",
"    The characterization of plaques with CCTA has also been evaluated as a means for identifying culprit lesions (ie, unstable plaque) in patients with chest pain. In preliminary studies, differences in plaque morphology and composition were noted between culprit lesions in acute coronary syndromes and stable lesions in patients with stable or unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCTA has been studied for use as a triage tool for patients undergoing evaluation for ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/67-69,71-73\">",
"     67-69,71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 103 consecutive patients who were admitted to the hospital without ischemic ECG changes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated biomarkers, 64-slice MDCT was shown to allow accurate triage. Both the absence of coronary plaque and significant coronary stenosis accurately predicted absence of ACS with a negative predictive value of 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study randomized 197 low-risk acute chest pain patients to either MDCT or standard diagnostic evaluation. MDCT allowed immediate diagnosis in 75 percent of patients, while further noninvasive testing was required in 25 percent due to intermediate stenosis severity or nondiagnostic image quality. Nevertheless, the MDCT group required fewer repeat evaluations for chest pain as compared to standard care and was associated with lowered costs and reduced time to diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interestingly, differences in plaque morphology and composition that have been noted between patients with stable or unstable angina may support the use of MDCT angiography over coronary calcium scoring to exclude ACS. In a study of 40 patients presenting with suspected ACS, a high prevalence of noncalcified plaques was observed. Moreover, in a substantial proportion of patients, CAD was present despite the absence of calcium. In total, 85 percent of patients with no calcium had atherosclerosis and in 39 percent a significant stenosis was identified, suggesting that the absence of coronary calcium does not reliably exclude the presence of CAD in patients with suspected ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no specific studies on CMRI in the setting of ACS. CMR studies performed in the setting of ACS have examined perfusion and function and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Ischemic heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Coronary venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the coronary venous system is of importance for certain electrophysiology procedures, such as left ventricular epicardial lead placement for cardiac resynchronization therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. CCTA and CMRI can both define coronary venous anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. However, the value of this information for the planning of such procedures has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Coronary artery stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A noninvasive angiographic technique to assess coronary stent patency would be highly desirable. In general, stents are difficult to visualize on CCTA because of image reconstruction artifacts in the presence of metal. Large caliber (&gt;3 to 3.5 mm) stents in the left main coronary artery, proximal segments of the other coronary arteries, or coronary artery bypass grafts have the highest likelihood of being imaged with diagnostic image quality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two studies have compared 64-slice MDCT to conventional coronary arteriography and confirmed its utility:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 125 stented lesions in 81 patients, the sensitivity and specificity for in-stent restenosis was 91 and 93 percent in evaluable segments (88 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/79\">",
"       79",
"      </a>",
"      ]. Vessel diameter was &ge;3.5 mm in 60 percent.",
"     </li>",
"     <li>",
"      In a series of 192 stented lesions in 182 patients, the sensitivity and specificity for in-stent restenosis was 95 and 93 percent in evaluable segments (93 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/80\">",
"       80",
"      </a>",
"      ]. Only stents &ge;2.5 mm in diameter were evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar high rates of sensitivity and specificity were noted in a series of patients with left main coronary artery in-stent restenosis in which the average vessel diameter was 3.4 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link\">",
"     \"Management of left main coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since no multivendor trial data are available for CCTA or current whole-heart CMRI, the broader applicability of research center results is not established [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/51\">",
"     51",
"    </a>",
"    ]. The value of CCTA and CMRI is expected to be highest if suitable patients and clinical questions are chosen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/69,70,82\">",
"     69,70,82",
"    </a>",
"    ]. Statements from national organizations for the use of CCTA and CMRI have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/82-85\">",
"     82-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the following recommendations from the 2008 American Heart Association (AHA) scientific statement on noninvasive coronary artery imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/82\">",
"     82",
"    </a>",
"    ] and the 2010 Expert Consensus Document on coronary computed tomographic angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/26/20906/abstract/83\">",
"     83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neither CCTA nor CMRI should be used to screen for coronary disease in patients who have no signs or symptoms suggestive of coronary artery disease.",
"     </li>",
"     <li>",
"      Noninvasive coronary angiography is reasonable for symptomatic patients who are at intermediate risk for coronary artery disease after initial risk stratification, including patients with equivocal stress test results. Diagnostic accuracy currently favors CCTA over CMRI for these patients.",
"     </li>",
"     <li>",
"      CCTA is NOT recommended in patients with either a very low pretest likelihood of coronary stenosis or a high pretest likelihood of coronary stenosis. Concerns about radiation exposure limit the use of CCTA in patients with very low likelihood of coronary disease. Patients with high likelihood of coronary artery disease are likely to require invasive coronary angiography and intervention.",
"     </li>",
"     <li>",
"      The usefulness of CCTA is reduced in patients with pronounced coronary calcification.",
"     </li>",
"     <li>",
"      CMRI or CCTA is suggested to evaluate suspected or known congenital or acquired coronary anomalies, particularly to establish the proximal course relative to the great vessels of coronary arteries with abnormal origin. CMRI is preferred in these younger patients to avoid radiation exposure and in patients with contraindications to iodinated contrast or beta blockers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCTA and CMRI are rapidly evolving technologies for the noninvasive visualization of the native coronary arteries and coronary artery bypass grafts. Current limitations are likely to be lessened with future improvements in technology.",
"   </p>",
"   <p>",
"    The broader applicability of CCTA and CMRI results from research centers has not generally been established. Local practice considerations, such as level of expertise, quality of the technology, and availability and quality of alternative diagnostic strategies, may influence decision making.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with no signs or symptoms suggestive of coronary artery disease, we recommended that neither CCTA nor CMRI should be used to screen for coronary disease.",
"     </li>",
"     <li>",
"      Noninvasive coronary angiography is reasonable for symptomatic patients who are at intermediate risk for coronary artery disease after initial risk stratification, including patients with equivocal stress test results. Diagnostic accuracy currently favors CCTA over CMRI for these patients.",
"     </li>",
"     <li>",
"      In patients with known or suspected congenital or acquired coronary anomalies, we suggest CCTA or CMRI. CMRI is preferred in younger patients given concerns about potential long-term effects of radiation associated with CCTA.",
"     </li>",
"     <li>",
"      In patients with coronary artery bypass grafts in whom it is not possible to selectively engage clinical important grafts during invasive angiography, we suggest CCTA or CMRI for evaluation of coronary artery bypass graft patency.",
"     </li>",
"     <li>",
"      In patients with contraindications to beta blockers or iodinated contrast or with significant renal dysfunction, CMRI is preferred to CCTA.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/1\">",
"      Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010; 362:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/2\">",
"      Manning WJ, Li W, Edelman RR. A preliminary report comparing magnetic resonance coronary angiography with conventional angiography. N Engl J Med 1993; 328:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/3\">",
"      Moshage WE, Achenbach S, Seese B, et al. Coronary artery stenoses: three-dimensional imaging with electrocardiographically triggered, contrast agent-enhanced, electron-beam CT. Radiology 1995; 196:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/4\">",
"      Jacobs JE, Boxt LM, Desjardins B, et al. ACR practice guideline for the performance and interpretation of cardiac computed tomography (CT). J Am Coll Radiol 2006; 3:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/5\">",
"      Woodard PK, Bluemke DA, Cascade PN, et al. ACR practice guideline for the performance and interpretation of cardiac magnetic resonance imaging (MRI). J Am Coll Radiol 2006; 3:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/6\">",
"      Dewey M, Schnapauff D, Teige F, Hamm B. Non-cardiac findings on coronary computed tomography and magnetic resonance imaging. Eur Radiol 2007; 17:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/7\">",
"      Onuma Y, Tanabe K, Nakazawa G, et al. Noncardiac findings in cardiac imaging with multidetector computed tomography. J Am Coll Cardiol 2006; 48:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/8\">",
"      Chan PG, Smith MP, Hauser TH, et al. Noncardiac pathology on clinical cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 2009; 2:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/9\">",
"      Leschka S, Alkadhi H, Plass A, et al. Accuracy of MSCT coronary angiography with 64-slice technology: first experience. Eur Heart J 2005; 26:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/10\">",
"      Leber AW, Knez A, von Ziegler F, et al. Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound. J Am Coll Cardiol 2005; 46:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/11\">",
"      Raff GL, Gallagher MJ, O'Neill WW, Goldstein JA. Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography. J Am Coll Cardiol 2005; 46:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/12\">",
"      Mollet NR, Cademartiri F, van Mieghem CA, et al. High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation 2005; 112:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/13\">",
"      Gerber TC, Kuzo RS, Lane GE, et al. Image quality in a standardized algorithm for minimally invasive coronary angiography with multislice spiral computed tomography. J Comput Assist Tomogr 2003; 27:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/14\">",
"      Heuschmid M, Kuettner A, Schroeder S, et al. ECG-gated 16-MDCT of the coronary arteries: assessment of image quality and accuracy in detecting stenoses. AJR Am J Roentgenol 2005; 184:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/15\">",
"      Hoffmann MH, Shi H, Manzke R, et al. Noninvasive coronary angiography with 16-detector row CT: effect of heart rate. Radiology 2005; 234:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/16\">",
"      Kefer J, Coche E, Legros G, et al. Head-to-head comparison of three-dimensional navigator-gated magnetic resonance imaging and 16-slice computed tomography to detect coronary artery stenosis in patients. J Am Coll Cardiol 2005; 46:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/17\">",
"      Langer C, Wiemer M, Peterschr&ouml;der A, et al. Images in cardiovascular medicine. Multislice computed tomography and magnetic resonance imaging: complementary use in noninvasive coronary angiography. Circulation 2005; 112:e343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/18\">",
"      Stuber M, Botnar RM, Danias PG, et al. Double-oblique free-breathing high resolution three-dimensional coronary magnetic resonance angiography. J Am Coll Cardiol 1999; 34:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/19\">",
"      Weber OM, Martin AJ, Higgins CB. Whole-heart steady-state free precession coronary artery magnetic resonance angiography. Magn Reson Med 2003; 50:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/20\">",
"      Budoff MJ, Cohen MC, Garcia MJ, et al. ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol 2005; 46:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/21\">",
"      Gerber TC, Kuzo RS, Karstaedt N, et al. Current results and new developments of coronary angiography with use of contrast-enhanced computed tomography of the heart. Mayo Clin Proc 2002; 77:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/22\">",
"      Budoff MJ, Lu B, Shinbane JS, et al. Methodology for improved detection of coronary stenoses with computed tomographic angiography. Am Heart J 2004; 148:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/23\">",
"      Gerber, TC, Breen, JF, Kuzo, RS, et al. Computed Tomographic Coronary Angiography: Techniques and Applications. Seminars in Ultrasound, CT and MRI 2006; 27:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/24\">",
"      Hamon M, Biondi-Zoccai GG, Malagutti P, et al. Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. J Am Coll Cardiol 2006; 48:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/25\">",
"      Vanhoenacker PK, Heijenbrok-Kal MH, Van Heste R, et al. Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease: meta-analysis. Radiology 2007; 244:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/26\">",
"      Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol 2008; 52:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/27\">",
"      Stein PD, Yaekoub AY, Matta F, Sostman HD. 64-slice CT for diagnosis of coronary artery disease: a systematic review. Am J Med 2008; 121:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/28\">",
"      Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008; 359:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/29\">",
"      Meijboom WB, Meijs MF, Schuijf JD, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol 2008; 52:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/30\">",
"      Rispler S, Keidar Z, Ghersin E, et al. Integrated single-photon emission computed tomography and computed tomography coronary angiography for the assessment of hemodynamically significant coronary artery lesions. J Am Coll Cardiol 2007; 49:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/31\">",
"      American College of Cardiology Foundation Task Force on Expert Consensus Documents, Hundley WG, Bluemke DA, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 121:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/32\">",
"      Kim WY, Danias PG, Stuber M, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001; 345:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/33\">",
"      Sakuma H, Ichikawa Y, Chino S, et al. Detection of coronary artery stenosis with whole-heart coronary magnetic resonance angiography. J Am Coll Cardiol 2006; 48:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/34\">",
"      Maintz D, Aepfelbacher FC, Kissinger KV, et al. Coronary MR angiography: comparison of quantitative and qualitative data from four techniques. AJR Am J Roentgenol 2004; 182:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/35\">",
"      Sommer T, Hackenbroch M, Hofer U, et al. Coronary MR angiography at 3.0 T versus that at 1.5 T: initial results in patients suspected of having coronary artery disease. Radiology 2005; 234:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/36\">",
"      Kato S, Kitagawa K, Ishida N, et al. Assessment of coronary artery disease using magnetic resonance coronary angiography: a national multicenter trial. J Am Coll Cardiol 2010; 56:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/37\">",
"      Bogaert J, Kuzo R, Dymarkowski S, et al. Coronary artery imaging with real-time navigator three-dimensional turbo-field-echo MR coronary angiography: initial experience. Radiology 2003; 226:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/38\">",
"      Schuijf JD, Bax JJ, Shaw LJ, et al. Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. Am Heart J 2006; 151:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/39\">",
"      Dewey M, Teige F, Schnapauff D, et al. Noninvasive detection of coronary artery stenoses with multislice computed tomography or magnetic resonance imaging. Ann Intern Med 2006; 145:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/40\">",
"      Dewey M, Teige F, Schnapauff D, et al. Combination of free-breathing and breathhold steady-state free precession magnetic resonance angiography for detection of coronary artery stenoses. J Magn Reson Imaging 2006; 23:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/41\">",
"      Pache G, Saueressig U, Frydrychowicz A, et al. Initial experience with 64-slice cardiac CT: non-invasive visualization of coronary artery bypass grafts. Eur Heart J 2006; 27:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/42\">",
"      Meyer TS, Martinoff S, Hadamitzky M, et al. Improved noninvasive assessment of coronary artery bypass grafts with 64-slice computed tomographic angiography in an unselected patient population. J Am Coll Cardiol 2007; 49:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/43\">",
"      Ropers D, Pohle FK, Kuettner A, et al. Diagnostic accuracy of noninvasive coronary angiography in patients after bypass surgery using 64-slice spiral computed tomography with 330-ms gantry rotation. Circulation 2006; 114:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/44\">",
"      White RD, Caputo GR, Mark AS, et al. Coronary artery bypass graft patency: noninvasive evaluation with MR imaging. Radiology 1987; 164:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/45\">",
"      Galjee MA, van Rossum AC, Doesburg T, et al. Value of magnetic resonance imaging in assessing patency and function of coronary artery bypass grafts. An angiographically controlled study. Circulation 1996; 93:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/46\">",
"      Molinari G, Sardanelli F, Zandrino F, et al. Value of navigator echo magnetic resonance angiography in detecting occlusion/patency of arterial and venous, single and sequential coronary bypass grafts. Int J Card Imaging 2000; 16:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/47\">",
"      Wintersperger BJ, Engelmann MG, von Smekal A, et al. Patency of coronary bypass grafts: assessment with breath-hold contrast-enhanced MR angiography--value of a non-electrocardiographically triggered technique. Radiology 1998; 208:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/48\">",
"      Langerak SE, Vliegen HW, Jukema JW, et al. Value of magnetic resonance imaging for the noninvasive detection of stenosis in coronary artery bypass grafts and recipient coronary arteries. Circulation 2003; 107:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/49\">",
"      Ropers D, Moshage W, Daniel WG, et al. Visualization of coronary artery anomalies and their anatomic course by contrast-enhanced electron beam tomography and three-dimensional reconstruction. Am J Cardiol 2001; 87:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/50\">",
"      Deibler AR, Kuzo RS, V&ouml;hringer M, et al. Imaging of congenital coronary anomalies with multislice computed tomography. Mayo Clin Proc 2004; 79:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/51\">",
"      Mavrogeni S, Papadopoulos G, Douskou M, et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol 2004; 43:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/52\">",
"      Greil GF, Stuber M, Botnar RM, et al. Coronary magnetic resonance angiography in adolescents and young adults with kawasaki disease. Circulation 2002; 105:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/53\">",
"      Iskandrian AE. Detecting coronary artery disease in left bundle branch block. J Am Coll Cardiol 2006; 48:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/54\">",
"      Meijboom WB, Mollet NR, Van Mieghem CA, et al. Pre-operative computed tomography coronary angiography to detect significant coronary artery disease in patients referred for cardiac valve surgery. J Am Coll Cardiol 2006; 48:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/55\">",
"      Gilard M, Cornily JC, Pennec PY, et al. Accuracy of multislice computed tomography in the preoperative assessment of coronary disease in patients with aortic valve stenosis. J Am Coll Cardiol 2006; 47:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/56\">",
"      Scheffel H, Leschka S, Plass A, et al. Accuracy of 64-slice computed tomography for the preoperative detection of coronary artery disease in patients with chronic aortic regurgitation. Am J Cardiol 2007; 100:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/57\">",
"      Andreini D, Pontone G, Pepi M, et al. Diagnostic accuracy of multidetector computed tomography coronary angiography in patients with dilated cardiomyopathy. J Am Coll Cardiol 2007; 49:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/58\">",
"      Ghostine S, Caussin C, Habis M, et al. Non-invasive diagnosis of ischaemic heart failure using 64-slice computed tomography. Eur Heart J 2008; 29:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/59\">",
"      Romeo G, Houyel L, Angel CY, et al. Coronary stenosis detection by 16-slice computed tomography in heart transplant patients: comparison with conventional angiography and impact on clinical management. J Am Coll Cardiol 2005; 45:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/60\">",
"      Sigurdsson G, Carrascosa P, Yamani MH, et al. Detection of transplant coronary artery disease using multidetector computed tomography with adaptative multisegment reconstruction. J Am Coll Cardiol 2006; 48:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/61\">",
"      Gregory SA, Ferencik M, Achenbach S, et al. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol 2006; 98:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/62\">",
"      Iyengar S, Feldman DS, Cooke GE, et al. Detection of coronary artery disease in orthotopic heart transplant recipients with 64-detector row computed tomography angiography. J Heart Lung Transplant 2006; 25:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/63\">",
"      Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation 2004; 109:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/64\">",
"      Fuster V, Fayad ZA, Moreno PR, et al. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005; 46:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/65\">",
"      Schoenhagen P, Tuzcu EM, Stillman AE, et al. Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: comparison of 16-slice computed tomography and intravascular ultrasound. Coron Artery Dis 2003; 14:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/66\">",
"      Achenbach S, Ropers D, Hoffmann U, et al. Assessment of coronary remodeling in stenotic and nonstenotic coronary atherosclerotic lesions by multidetector spiral computed tomography. J Am Coll Cardiol 2004; 43:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/67\">",
"      Hoffmann U, Moselewski F, Nieman K, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol 2006; 47:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/68\">",
"      Hausleiter J, Meyer T, Hadamitzky M, et al. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol 2006; 48:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/69\">",
"      Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007; 50:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/70\">",
"      Pundziute G, Schuijf JD, Jukema JW, et al. Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol 2007; 49:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/71\">",
"      Hoffmann U, Nagurney JT, Moselewski F, et al. Coronary multidetector computed tomography in the assessment of patients with acute chest pain. Circulation 2006; 114:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/72\">",
"      Goldstein JA, Gallagher MJ, O'Neill WW, et al. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007; 49:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/73\">",
"      Henneman MM, Schuijf JD, Pundziute G, et al. Noninvasive evaluation with multislice computed tomography in suspected acute coronary syndrome: plaque morphology on multislice computed tomography versus coronary calcium score. J Am Coll Cardiol 2008; 52:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/74\">",
"      Singh JP, Houser S, Heist EK, Ruskin JN. The coronary venous anatomy: a segmental approach to aid cardiac resynchronization therapy. J Am Coll Cardiol 2005; 46:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/75\">",
"      Jongbloed MR, Lamb HJ, Bax JJ, et al. Noninvasive visualization of the cardiac venous system using multislice computed tomography. J Am Coll Cardiol 2005; 45:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/76\">",
"      Gerber TC, Sheedy PF, Bell MR, et al. Evaluation of the coronary venous system using electron beam computed tomography. Int J Cardiovasc Imaging 2001; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/77\">",
"      Nezafat R, Han Y, Peters DC, et al. Coronary magnetic resonance vein imaging: imaging contrast, sequence, and timing. Magn Reson Med 2007; 58:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/78\">",
"      Ligabue G, Rossi R, Ratti C, et al. Noninvasive evaluation of coronary artery stents patency after PTCA: role of Multislice Computed Tomography. Radiol Med 2004; 108:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/79\">",
"      Ehara M, Kawai M, Surmely JF, et al. Diagnostic accuracy of coronary in-stent restenosis using 64-slice computed tomography: comparison with invasive coronary angiography. J Am Coll Cardiol 2007; 49:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/80\">",
"      Cademartiri F, Schuijf JD, Pugliese F, et al. Usefulness of 64-slice multislice computed tomography coronary angiography to assess in-stent restenosis. J Am Coll Cardiol 2007; 49:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/81\">",
"      Van Mieghem CA, Cademartiri F, Mollet NR, et al. Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. Circulation 2006; 114:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/82\">",
"      Bluemke DA, Achenbach S, Budoff M, et al. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the american heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young. Circulation 2008; 118:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/83\">",
"      Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol 2006; 48:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/84\">",
"      Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/26/20906/abstract/85\">",
"      American College of Cardiology Foundation Task Force on Expert Consensus Documents, Mark DB, Berman DS, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010; 55:2663.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5308 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20906=[""].join("\n");
var outline_f20_26_20906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Per patient versus per segment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidental findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiac and coronary CT imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - MDCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CORONARY ARTERY STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Coronary CT angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Test methodology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Impact of coronary calcification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Single center studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Multicenter studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Combined testing with SPECT rMPI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Coronary MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Comparison of CCTA and CMRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CORONARY ARTERY BYPASS GRAFT STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Coronary CT angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Coronary MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CORONARY ARTERY ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Congenital anomalies of origin and course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Coronary artery aneurysms/Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Before non-coronary cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Plaque imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Coronary venography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Coronary artery stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16952?source=related_link\">",
"      Full body CT scan for screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=related_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=related_link\">",
"      Radiation dose and risk of malignancy from cardiovascular imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_26_20907="Lab features in malabsorption";
var content_f20_26_20907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory features of malabsorption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Decreased",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemoglobin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum or RBC folate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Serum",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Iron",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Ferritin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Vitamin B12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Calcium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Magnesium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cholesterol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Carotene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Albumin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       25-hydroxyvitamin D",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Increased",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxalate in urine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prothrombin time",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum total iron binding capacity",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20907=[""].join("\n");
var outline_f20_26_20907=null;
var title_f20_26_20908="Risk stratification for syncope";
var content_f20_26_20908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk stratification for syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         SHORT-TERM HIGH RISK CRITERIA WHICH REQUIRE PROMPT HOSPITALIZATION OR INTENSIVE EVALUATION",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Severe structural or coronary artery disease",
"        </strong>",
"        (heart failure, low LVEF, or previous myocardial infarction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Clinical or ECG features suggesting arrhythmic syncope",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Syncope during exertion or supine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Palpitations at the time of syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Family history of SCD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Non-sustained VT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Bifascicular-block (LBBB or RBBB combined with left anterior or left posterior fascicular block) or other intraventricular conduction abnormalities with QRS duration &ge;120 ms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Inadequate sinus bradycardia (&lt;50 bpm) or sinoartrial block in absence of negative chronotropic medications or physical training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Pre-excited QRS complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Prolonged or short QT interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - RBBB pattern with ST-elevation in leads V1-V3 (Brugada pattern)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Negative T waves in right precordial leads, epsilon waves, and ventricular late potentials suggestive of ARVC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Important co-morbidities",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Severe anaemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Electrolyte disturbance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARVC: arrhythmogenic right ventricular cardiomyopathy; bpm: beats per minute; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; RBBB: right bundle branch block; SCD: sudden cardiac death; VT: ventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20908=[""].join("\n");
var outline_f20_26_20908=null;
var title_f20_26_20909="Methamphetamine intoxication in adults - Rapid overview";
var content_f20_26_20909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methamphetamine intoxication in adults: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be abused by nasal, oral, or intravenous route",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid onset of symptoms with long (~24 hours) duration of action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History may be difficult to obtain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe agitation can occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sympathomimetic toxidrome frequently present:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; CNS stimulation (agitation, delirium or acute psychosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Dilated pupils (mydriasis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Diaphoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthermia (variable; may be severe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory analysis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Routine testing in poisoned patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Fingerstick glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; ECG to assess for conduction system impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Acetaminophen and salicylate levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Pregnancy test in women of childbearing age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Basic electrolytes, BUN, creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Metabolic acidosis, acute renal failure, and hyperkalemia may be seen in severe toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creatinine phosphokinase, serum lactate, aminotransferases, coagulation studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Agitation (control with aggressive sedation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Benzodiazepines are first line therapy; may need large doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; For severe agitation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Lorazepam, 4 mg IV, may repeat every 8 to 10 minutes, titrate to sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Diazepam, 5 to 10 mg IV, may repeat every 8 to 10 minutes, titrate to sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - If lacks IV access, midazolam 5 to 10 mg intramuscularly, may repeat every 10 minutes, titrate to sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Consider other agents (see text) in cases of benzodiazepine failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paralysis and tracheal intubation may be necessary; succinylcholine should",
"        <strong>",
"         not",
"        </strong>",
"        be used for rapid sequence intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Critical hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Benzodiazepines are first line therapy (see dosing above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Nitroprusside: start at 0.25 to 0.5 mcg/kg/min; titrate to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Phentolamine: 2-5 mg IV, may repeat; titrate to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull;",
"        <strong>",
"         AVOID BETA BLOCKING AGENTS, INCLUDING LABETALOL",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hyperthermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Sedation with benzodiazepines (see dosing above);",
"        <strong>",
"         DO NOT",
"        </strong>",
"        give antipyretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Evaporative cooling measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Cooling blankets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Neuromuscular paralysis in severe cases",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20909=[""].join("\n");
var outline_f20_26_20909=null;
var title_f20_26_20910="Mortality VPBs during exercise";
var content_f20_26_20910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Ventricular arrhythmia during exercise predicts an increased cardiac mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 354px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 6101 normal men who underwent exercise testing and were followed for 23 years, the occurrence of ventricular premature beats (VPBs) during exercise testing was associated with a significantly higher all-cause mortality (41 versus 26 percent for no VPBs) and death from cardiovascular disease (16 versus 6.4 percent). After adjusting for age, tobacco use, diabetic status, body-mass index, level of physical activity, systolic blood pressure, the heart rate at rest, and total cholesterol level the presence of VPBs prior to or during exercise was an independent predictor of cardiovascular mortality (relative risk 2.53) and had the same prognostic value as exercise induced ischemia (relative risk 2.63).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jouven X, Zureik M, Desnos M, et al. N Engl J Med 2000; 343:826.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20910=[""].join("\n");
var outline_f20_26_20910=null;
var title_f20_26_20911="Sensitivity cancer screening";
var content_f20_26_20911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Calculating sensitivity of a cancer screening test according to the detection method and the incidence method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher RH, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_26_20911=[""].join("\n");
var outline_f20_26_20911=null;
